



Cite this: *Mol. BioSyst.*, 2015,
11, 434

Temporal-logic analysis of microglial phenotypic conversion with exposure to amyloid- β [†]

Thomas J. Anastasio

Alzheimer Disease (AD) remains a leading killer with no adequate treatment. Ongoing research increasingly implicates the brain's immune system as a critical contributor to AD pathogenesis, but the complexity of the immune contribution poses a barrier to understanding. Here I use temporal logic to analyze a computational specification of the immune component of AD. Temporal logic is an extension of logic to propositions expressed in terms of time. It has traditionally been used to analyze computational specifications of complex engineered systems but applications to complex biological systems are now appearing. The inflammatory component of AD involves the responses of microglia to the peptide amyloid- β (A β), which is an inflammatory stimulus and a likely causative AD agent. Temporal-logic analysis of the model provides explanations for the puzzling findings that A β induces an anti-inflammatory and well as a pro-inflammatory response, and that A β is phagocytized by microglia in young but not in old animals. To potentially explain the first puzzle, the model suggests that interferon- γ acts as an "autocrine bridge" over which an A β -induced increase in pro-inflammatory cytokines leads to an increase in anti-inflammatory mediators also. To potentially explain the second puzzle, the model identifies a potential instability in signaling via insulin-like growth factor 1 that could explain the failure of old microglia to phagocytize A β . The model predicts that augmentation of insulin-like growth factor 1 signaling, and activation of protein kinase C in particular, could move old microglia from a neurotoxic back toward a more neuroprotective and phagocytic phenotype.

Received 1st August 2014,
Accepted 21st October 2014

DOI: 10.1039/c4mb00457d

www.rsc.org/molecularbiosystems

Introduction

Alzheimer Disease (AD) is a neurodegenerative disorder of high prevalence that currently is the sixth leading cause of death in the United States (www.alz.org). It has a complex, multifactorial etiology. Clinical and epidemiological evidence increasingly indicates that inflammation plays an important role in AD pathogenesis.¹ The inflammatory response is highly complex in its own right. A large number of experimental observations on specific aspects of the inflammatory component of AD have accumulated, and effectively aggregating these into a format usable for data interpretation and hypothesis generation presents a critical challenge. The purpose of the research described here is to use specialized computational methods to specify the interactions between many of the molecules and cellular processes thought to be involved in the inflammatory component of AD, and then use temporal logic to analyze them. The data-driven specification represents experimental findings as reported, and is

course-grained but thorough. Analysis of the model provides new insights into the nature of the inflammatory response in AD and makes several experimentally testable predictions.

The pathological hallmark of the AD brain is the presence of plaques composed of the peptide amyloid- β (A β)² (see ESI,[†] Table S1 for all abbreviations). Over accumulation of A β is toxic to neurons and is thought to contribute to AD pathology.³ The inflammatory response in the brain is mediated by microglia, which are the brain's main immune cells and are found in abundance around A β plaques.^{1,4} Among other human AD concomitants, A β plaques and brain inflammation are also observed in A β -overproducing transgenic-mouse AD models.⁵

Epidemiological studies indicate that chronic use of NSAIDs is protective against AD,⁶ and that the benefit may result mainly from a reduction in brain inflammation due to NSAIDs.⁷ Studies using transgenic AD mice show that NSAIDs can reduce soluble A β levels and A β deposits in brain, and can also reduce microglial activation, levels of pro-inflammatory factors such as IL1 β and PGE2, and activation of NF κ B.⁸ Further experiments in transgenic AD mice reveal that microglia are involved at different stages of the disease process. In early stages, microglia assume a phagocytic state in which they clear A β , but in later stages they switch to a cytotoxic state in which they release inflammatory cytokines such as IL1 β and TNF α , which are toxic to neurons at high levels.^{1a}

Computational Neurobiology Laboratory, Department of Molecular and Integrative Physiology, and Beckman Institute for Advanced Science and Technology, University of Illinois at Urbana-Champaign, Urbana, IL, USA. E-mail: tja@illinois.edu

[†] Electronic supplementary information (ESI) available. See DOI: 10.1039/c4mb00457d

These results in transgenic AD mice suggest a possible approach to the treatment of AD in which microglia are maintained in the phagocytic phenotype, or even converted from the inflammatory to the phagocytic phenotype. The analysis presented in this paper is focused on a computational assessment of that possibility, and on the cytokines and other factors that regulate microglial phenotype. The details of the phagocytic process itself are not considered. Although complement components and chemokines also may be involved in AD pathogenesis, they are excluded from the model because their role in microglial activation in AD is not yet clear.^{1f,9}

Other potential contributors are also excluded. For example, brain inflammation can lead to infiltration of bone marrow-derived monocytes that could become microglia in the brain, and these could also play a role in A β clearance,¹⁰ but the conditions under which this occurs are still in question.^{1f} A recent pathology study showed that the total number of microglia remains constant over the course of AD in human brain but that the ratio of activated to resting microglia increases, indicating that microglial responses in AD are largely due to a phenotypic conversion of resting microglia rather than to proliferation of microglia or to infiltration of monocytes into brain.¹¹ Also, T-cells infiltrate the brain in transgenic AD mice at advanced ages,¹² and antibodies against A β can reduce A β load in transgenic AD mice and humans but can also cause meningoencephalitis associated with T-cell infiltration into brain.¹³ The potential contribution to the microglial population of infiltrating bone marrow-derived monocytes or other immune cells is not considered here in order to focus on phenotypic changes of brain-resident microglia. Finally, astrocytes, which are the most abundant type of glial cell, also participate in the brain's inflammatory response,¹⁴ but their contribution is not considered here in order to focus on the microglial contribution.

The computational analysis presented here revolves around salient and general findings concerning microglial phenotype in the presence of A β . The data are derived mainly from experiments in mice. The general observations are that A β exposure causes microglia to produce both pro-inflammatory and anti-inflammatory cytokines, that A β exposure increases phagocytosis in microglia from "young" mice but decreases it in microglia from "old" mice (roughly less than or greater than one year old, respectively), and that the old, non-phagocytic phenotype is persistent in that it is maintained once it is adopted. Among other results, the analysis suggests that IFN γ might provide an "autocrine bridge" over which an initially pro-inflammatory stimulus such as A β could increase production of anti-inflammatory cytokines. It also identifies IGF1 as another autocrine bridge over which the phagocytic state of microglia could potentially be promoted. The model makes predictions of therapeutic relevance on the basis of these findings.

The computational analysis employs techniques from formal methods in computer science.¹⁵ A formal methods analysis of a system is based on a computational representation of that system in a declarative programming language, which offers analysis capabilities not available to programs written in more conventional, imperative languages. Whereas a statement in an imperative language is a command, a statement (or declaration)

in a declarative language is a fact. A declarative program, in which the statements describe the facts concerning the interactions between the elements of the system being modeled, is known as a system specification. The main advantage of specifications written in declarative languages is that they can be used not only for simulation but also can be analyzed using temporal logic and state-space search.¹⁶ When the specification is composed of facts that are true concerning the system, temporal logic analysis and state-space search can be used essentially to prove what else is true for that system.

In principle, a declarative language can be used to specify a system at any level of numerical accuracy, but in practice the temporal-logic capabilities of the declarative environment are facilitated by limiting system elements to integer levels of activation (a course-grained representation). For this analysis, element activations are limited to the integers in the range [0, 10]. Limiting element activations to the Boolean {0, 1} has a long history in systems biology,¹⁷ and this approach is undergoing continuous development.¹⁸ Modeling paradigms that limit element activations to integer levels include those based on multivalued logic or Petri nets.¹⁹ Temporal-logic analysis of declarative specifications of biological systems, as implemented here, is a relatively new trend.²⁰ Logic-based models can capture the essential features of biological system behavior and are appropriate in the many contexts in which the parameters needed for kinetic, differential-equation-based models, such as concentrations and reaction rates, are not known.^{20,21} The overall goal of the logic-based approach is to represent a biological system in a course-grained but thorough fashion and to develop, through rigorous analysis, a detailed understanding of the mechanistic events that underlie its behavior.

The focus here is on the system of molecular and cellular interactions that determine microglial phenotype in AD. They are specified using a declarative programming language known as Maude.²² Maude was designed for modeling and analysis of complex systems. So far Maude has been used mainly to model complex engineered systems such as computer operating systems, internet protocols, and even other programming languages.²³ Some applications of Maude to biological systems have also appeared.²⁴ Recently, Maude has been applied to problems in AD pathophysiology.²⁵ This work can be consulted for further background on Maude and on how it can be applied to biological systems.

A declaration in a declarative language specifies how a term matching its left-hand side should be replaced by a term matching its right-hand side. Declarations in Maude are of two types: equations and rules. Equations elaborate the current state of the system model while rules transition the system from one state to another. Maude performs search and temporal-logic analysis of system models by first generating the entire state-transition tree, taking all possible trajectories through the state space and finding all possible terminal states (a.k.a. steady states). Then state-space search is used to find specific states of interest, while temporal-logic analysis is used to verify time-qualified propositions such as whether a specific state always occurs, eventually occurs, does not occur until another specific state occurs, and so on.

For the microglia system model, the declarations describing autocrine updates (*i.e.* updates of microglial receptors to factors generated by the microglia themselves) are expressed as rules. All other declarations are expressed as equations. In this way the state of the microglia system model is advanced each time one of its receptors is updated by a self-generated factor. This approach facilitates analysis of the microglia system and leads to potential new insights into the behavior of microglia in the AD brain.

Experimental background and model construction

The model is based on molecular and cellular interactions as determined through focused laboratory-based experiments and as described in the literature. Only statistically significant interactions are included in the model. The next subsection describes in detail the experimental findings on which the model is based, while the subsection following describes construction of the computational model.

Biological interactions represented in the model

Microglia are endowed with a large variety of receptors and receptor complexes and can be induced, *via* signaling cascades proceeding from them, into inflammatory or phagocytic phenotypes.⁴ The specific phenotype they assume is most likely determined by the combination of receptors that are activated, which in turn is determined by the ligands that are present, which in turn is determined by the state of the organism. A large literature implicates A β as a key ligand in the AD brain.

A β tends to self-aggregate into soluble oligomers of low order, into fibrils, and into plaques.²⁶ Microglia respond to and phagocytize mainly fibrillar A β (fA β). Fibrillar A β binds to a microglial receptor complex (the TLR complex) composed of the toll-like receptors TLR2 and TLR4, along with the co-receptors SRA, CD14, CD36, CD47, and the α 6 β 1 integrin.²⁷ Activation of the TLR complex leads to phosphorylation of the Lyn and Syk kinases in microglia in culture.²⁸ Lyn and Syk can both phosphorylate Vav, and Vav can then load a GTP onto the GTPase Rac.²⁹ Rac is also part of the NADPH oxidase complex, and Rac activation can lead to the production of ROS by the NADPH complex.³⁰

TLR2 and TLR4 also signal through the adaptor protein MyD88, and TLR4 separately signals through the TRIF protein.^{4b,27b} MyD88 activates IRAK, and IRAK associates with TRAF6.³¹ TRAF6 activates TAK1, and TAK1 then activates IKK, which inactivates I κ B, which releases and thereby activates NF κ B. TAK1 also activates MAP3K, which activates MAP2K, which activates MEK. MEK activates ERK, as well as p38MAPK and JNK, leading to activation of AP1. Independently of MyD88, TLR4 also activates TRIF, which activates RIP1, and RIP1 also activates TAK1. Thus, the MyD88–TRAF6 and TRIF–RIP1 pathways are parallel pathways leading to activation of TAK1.^{4b} Activation of NF κ B or AP1 promotes expression of pro-inflammatory mediators.^{27d}

Activation by fA β of the TLR complex can cause various microglial reactions, which depend on factors that in turn depend on age. Experiments using transgenic AD mice that are also deficient in TLRs show that A β activation of TLR2/4 reduces A β load as the mice age, and increases production of pro-inflammatory cytokines such as IL1 β , IL17, and TNF α but also increases production of anti-inflammatory cytokines and other factors such as IL10 and TGF β .³² TGF β signals through its receptor TGFR and transcription factors known as Smad proteins.³³ TGF β promotes A β phagocytosis by microglia.³⁴ In transgenic AD mice with normal TLRs, microglia transition from a phagocytic form at age 6 months (young) to the classic, cytotoxic form at age 18 months (old).¹² The switch is coincident with high levels of A β and of inflammatory mediators including IL1 β , TNF α , NADPH oxidase, and COX2. Although expression of the tissue-repair factor Arg1 is not increased, levels of the related factor Ym1 are increased in young transgenics while the anti-inflammatory IL4, IL10, and TGF β are increased in old transgenics.¹² These results indicate that microglia in transgenic, A β -overproducing mice start out phagocytizing A β but end up becoming predominantly inflammatory and cytotoxic, and this compromises their ability phagocytize A β .

Studies in which levels of inflammatory cytokines are increased in mice, either through genetic overexpression or direct administration, show that augmentation of inflammatory cytokines can actually promote A β phagocytosis in young mice but suppress it in old mice. Local brain (hippocampal) overexpression of IL1 β in young wild-type mice increases production of IL1 β , IL6, and TNF α , while in young transgenic AD mice, local overexpression of IL1 β actually reduces the A β load.³⁵ Administration of IL6 induces a microgliosis that reduces A β deposition in young AD transgenic mice.³⁶ However, as the mice age, increasing levels of inflammatory cytokines such as IL1 β , IL6, and TNF α lead to decreasing phagocytic ability in microglia.³⁷ Transgenic AD mice that lack the pro-inflammatory IL12 and IL23 have a lower A β load than do the same mice that have normal levels of IL12 and IL23 as they age.³⁸ The inflammatory effects of IL1 β are suppressed to some extent by the naturally-occurring IL1 receptor antagonist IL1Ra.³⁹ These results suggest that in young mice, inflammatory cytokines actually induce microglial phagocytosis of A β but in old mice, inflammatory cytokines induce a more cytotoxic microglial phenotype with suppressed phagocytic ability.

Studies using isolated microglia in culture paint a similar picture. In microglia from young mice, activation by fA β leads to ROS production and phagocytosis, and this is attenuated, but not eliminated, in Vav knockout microglia.²⁹ IL6 induces microglia from young mice to increase A β phagocytosis and to increase Ym1 but not Arg1.³⁶ IL6 signals through STAT3 *via* the IL6 receptor IL6R and JAK2 in certain cell lines⁴⁰ and possibly also in microglia. TNF α induces microglia from young mice to increase A β phagocytosis.⁴¹ In contrast, in old mice, microglia produce more IL1 β and TNF α and phagocytize less A β .^{37b} Binding of fA β to the TLR complex in the N9 microglial cell line causes an increase in IL1 β and IL6.⁴² These results indicate that A β or inflammatory cytokines can increase phagocytosis by microglia in young brains but decrease it in old brains.

IL4 emerges from studies of microglia in culture as a factor potentially useful for maintaining microglia in a phagocytic state, while IFN γ presents a mixed picture. In one study, fA β causes neonatal microglia to increase TNF α but to decrease the anti-inflammatory IGF1. This pro-inflammatory response is blunted if microglia are pretreated with IL4 or, to a lesser extent, with IFN γ .⁴³ By itself, IL4 increases IGF1 and decreases TNF α while IFN γ does the opposite. Pretreatment with A β does not alter IL4-induced IGF1 expression. Taken together, these results show that IL4 is much better at preserving the neuroprotective state than IFN γ , while IFN γ has mixed but interesting properties. Antibodies against IGF1 significantly weaken the neuroprotective effect of IL4, suggesting that IL4 exerts its effect mainly through IGF1.⁴³

In a related study, IFN γ is shown to stimulate secretion of TNF α and production of iNOS from wild-type microglia isolated from old mice, but not from microglia from mice with the interferon receptor IFNR knocked out.⁴⁴ However, fA β causes IFN γ secretion from microglia independently of IFNR. IL4 signals through STAT6 *via* the IL4 receptor (IL4R) and JAK1,⁴⁵ while IFN γ signals through JAK2/STAT1.⁴⁶ IGF1 reduces ROS and TNF α production by inflammatory microglia, and these effects are thought to result from activation of the IGF2 receptor IGF2R and/or a hybrid of the insulin receptor IR and IGF1R (IRIGF1R).⁴⁷ IGF1, IGF2, and insulin each have affinity for IGF1R, IGF2R, IR, and IRIGF1R.⁴⁸ Activation by IGF1 of IRIGF1R could reduce ROS *via* the pathway PI3K to Akt to FOXO to SOD, while activation by IGF1 of IGF2R could reduce TNF α *via* the pathway Gq to PKC.⁴⁸

Several studies applied the endotoxin LPS to microglia in culture to explore inflammatory reactions and changes in A β phagocytosis. LPS binds with the TLR complex and in low doses can induce the phagocytic microglial phenotype.⁴⁹ At higher doses, LPS causes microglia isolated from young mice to substantially increase their production of the pro-inflammatory cytokines TNF α , IL1 β , IL6, and IL12, and to increase the anti-inflammatory IL10.⁵⁰ These results are largely confirmed and extended in a more recent study that employs a more stringent isolation technique.⁵¹ LPS causes pure postnatal murine microglia to increase production both of TNF α and TGF β . Also in these microglia, TGF β production is increased by TNF α but TNF α production is decreased by TGF β . Like LPS, IFN γ causes these microglia to increase production both of TNF α and TGF β (the reported TGF β increase was not significant). LPS causes microglia isolated from neonatal rats to decrease production of IGF1, but LPS does not substantially diminish the increase in IGF1 produced by IL4.⁴³ BV2 (immortalized murine microglial cell line) microglia reduce their level of Arg1 production when exposed to high-dose LPS.⁵²

In comparison with young microglia, exposure to LPS of microglia isolated from old mice causes them to produce even more TNF α , IL1 β , IL6, and IL12.⁵⁰ Old microglia do not decrease TGF β production with LPS exposure but they actually produce more IL10. Activation of microglia using LPS and fA β promotes a predominantly inflammatory phenotype and synergistically increases secretion of IL1 β and decreases secretion of IL4.^{1d}

Pretreatment using LPS or pro-inflammatory mediators including IL1 β , TNF α , or IFN γ inhibits the fA β -induced phagocytosis of fA β by primary murine or BV2 microglia.⁵³ The resulting pro-inflammatory suppression of phagocytosis can be relieved by NF κ B inhibitors, by the anti-inflammatory cytokines IL4, IL10, IL13, and TGF β , by COX2 inhibitors such as NSAIDs, or by an antagonist of the prostanoid receptor EP2. Ablation of EP2 substantially suppressed microglial production of the pro-inflammatory mediators iNOS and COX2, and enhanced A β phagocytosis by microglia.⁵⁴ The enhancement of phagocytosis by EP2 ablation is completely prevented by inhibition of PKC, suggesting that EP2 normally suppresses microglial phagocytosis by inhibiting PKC.

Several studies point to PPAR γ as a key player in the determination of microglial phenotype and as a mediator of the beneficial effects of NSAIDs, since NSAIDs increase PPAR γ expression.⁵⁵ If initiated while the animals are still young, treatment of transgenic AD mice with the NSAID ibuprofen reduces IL1 β , both soluble and aggregated A β , and the number of pro-inflammatory microglia.^{8a} Similar treatment of transgenic AD mice with ibuprofen also reduces A β plaques and expression of COX2 and iNOS, while treatment with the PPAR γ agonist pioglitazone does the same but to an even greater extent.⁵⁶ Rosiglitazone, another PPAR γ agonist, reduces IL1 β , iNOS, and NO but increases IL4 in the hippocampus of old rats.⁵⁷

PPAR γ forms a heterodimer with RXR before binding PPAR response elements and opposing NF κ B but promoting expression of anti-inflammatory mediators. Both pioglitazone and the PPAR γ modulator DSP-8658 enhanced the phagocytosis of A β by microglia.⁵⁸ Retinoic acid or bexarotene, which are both RXR agonists, also enhance microglial A β phagocytosis.

LXR β also forms a dimer with RXR, and LXR β knockout increases A β load in AD transgenic mice.⁵⁹ Ligands of LXR β suppress development of the pro-inflammatory phenotype and contribute to the maintenance of the phagocytic phenotype in microglia exposed to fA β . Ligands of LXR β also suppress LPS- or IL1 β -induced production by microglia of iNOS, NO, COX2, TNF α , and IL1 β itself, and reverse the inhibition by LPS or IL1 β of fA β -induced A β phagocytosis by microglia. These data suggest that LXR β demotes the inflammatory and promotes the phagocytic phenotype in a manner similar to that of PPAR γ . Also, NaHS, a donor of H₂S, reduces A β -induced microglial production of IL1 β , IL6, TNF α , and COX2 by inhibiting the activation of NF κ B.⁶⁰ Though PPAR γ opposes NF κ B, NF κ B can also oppose PPAR γ . In macrophages, activation of TLR2/4 reduces PPAR γ expression at the mRNA level, but this is prevented by inhibition of IKK or NF κ B.⁶¹ NF κ B-induced reduction in PPAR γ expression is associated with increased production of pro-inflammatory cytokines including TNF α . These findings reveal a mutually antagonistic interaction between PPAR γ and NF κ B in macrophages.

An important class of modulators of microglial phenotype are factors attached to or secreted by neurons, and some of these counter the anti-inflammatory, phagocytic phenotype. The CD40 ligand CD40L suppresses the phagocytic response to fA β of BV cells or of primary murine microglia.⁵³ Knockout of the CD40L gene in transgenic AD mice results in reduced A β plaques and reduced microgliosis and TNF α expression.⁶²

Microglia derived from neonatal rats take up more A β when pretreated with IL4 if they do not express CD40.⁶³

Conversely, most of the neuronal membrane-bound or secreted factors seem to maintain microglia in the phagocytic state. Recent genomewide association studies show that homozygous loss-of-function mutations in the gene encoding TREM2 are associated with a significant risk for AD.⁶⁴ The TREM2 ligand TREM2L is expressed on neural membranes.⁶⁵ TREM2 signals *via* DAP12.⁶⁶ Activation of TREM2 phosphorylates DAP12, which provides a docking site for Syk. Syk promotes phosphorylation of GRB2, which leads to activation of ERK, which in turn leads to reorganization of the cytoskeleton and increased phagocytosis in microglia.^{65a,67} Myeloid precursor cells (which can become microglia) that overexpress TREM2 show increased phagocytosis, but this is blocked by inhibition of ERK.⁶⁸ They also produce more IL10, but less of each of IL1 β , iNOS, TNF α , and IFN γ . Knockdown of TREM2 in microglia inhibited phagocytosis and increased production of TNF α , IL1 β , IL12, and iNOS. Stimulation by ligands of TLR2 (which include A β) leads to inhibition of TNF α production by microglia, but only if TREM2 is available to phosphorylate DAP12.⁶⁹

Other membrane-bound factors that help keep microglia in a neuroprotective state include CD22 and CD200.^{65b} The neuronal membrane-bound CD45 ligand CD22, which can also be secreted by neurons in soluble form, inhibits LPS-induced TNF α secretion by microglia.⁷⁰ Neurons express CD200 while microglia express the CD200 receptor CD200R.⁷¹ CD200 expressed on neurons significantly attenuates A β -induced secretion by microglia of IL1 β , IL6, and TNF α . In mouse bone marrow-derived mast cells, activation by CD200 of CD200R inhibits signaling *via* the ERK, JNK, and p38MAPK pathways.⁷² Binding of CD200 to CD200R causes CD200R phosphorylation and binding of CD200R to docking proteins Dok1 and Dok2. Dok1 binds SHIP1 and both Dok1 and Dok2 recruit GAP. GAP then inhibits Ras. Since Ras activates ERK, CD200/CD200R inhibits ERK *via* this mechanism. How CD200R inhibits JNK and p38MAPK is not known. CD200 expression decreases with age and also decreases as a result of A β application, and both CD200 and CD200R expression are reduced in the human AD brain, specifically in the hippocampus and cerebral cortex.⁷³

Fractalkine is enigmatic in that it seems to promote either microglial phenotype, depending on circumstances. Fractalkine (a.k.a. CX3CL1) is expressed by neurons throughout the brain and can exist either in membrane-bound or soluble form.⁷⁴ Deficiency of the fractalkine receptor CX3CR1 causes microglia to become neurotoxic.^{65b,75} This result suggests that fractalkine promotes the neuroprotective, phagocytic phenotype. However, transgenic AD mice have reduced A β deposition and increased A β phagocytosis if they are also deficient *via* gene knockout in CX3CR1.⁷⁶ The CX3CR1 deficiency decreases production of TNF α , but increases production of IL1 β , by microglia in transgenic AD mice. In culture, CX3CL1 reduces phagocytosis of A β by microglia.⁷⁶ Thus, fractalkine is like IFN γ in that it can promote either the neurotoxic or the neuroprotective phenotype, but in suppressing IL1 β while enhancing TNF α its effects are even more ambiguous. Transgenic AD mice produce fewer fractalkine

positive cells than wild type when younger but fractalkine levels decrease in both and even out when older.⁷⁷

While healthy neurons express proteins that suppress the pro-inflammatory microglial phenotype, necrotic neurons express proteins that enhance it. Necrotic neurons, but not other necrotic cell types, can induce the pro-inflammatory phenotype of microglia through a signaling cascade involving MyD88.⁷⁸ Microglia induced by necrotic neurons have increased production of IL6, IL12, TNF α , NO, and CD40.

Another factor important for the determination of microglial phenotype in AD is ACh. AD is associated with loss of cholinergic neurons early in the disease process.⁷⁹ Microglia express the ACh receptor $\alpha 7$ nAChR.⁸⁰ Pretreatment with ACh or nicotine inhibits the LPS-induced release from microglia of TNF α .^{80a,81} This inhibition is mediated by a reduction in phosphorylation of p38MAPK and JNK.⁸² The mechanism is not known but it appears to occur without the influx of extracellular calcium.^{81,83} Activation of $\alpha 7$ nAChR by nicotine also reduces ROS production by preventing NADPH activation.⁸³ Donepezil, a widely used anticholinesterase, attenuates the A β -induced release of the inflammatory mediators IL1 β , TNF α , PGE2, and NO, and reduces the upregulation of iNOS and COX2, the phosphorylation of p38MAPK, and the activation NF κ B in microglia.⁸⁴ The interactions outlined in this subsection are diagrammed in Fig. 1 and specified computationally as described in the next subsection. Data from this subsection that are used to verify the model are summarized in Table 1.

Computational representation of microglia signaling

Computational representation of the microglia signaling system begins by representing its constituent molecules (and some cellular processes) as elements of the model, and proceeds by specifying the interactions between those elements. The main focus of this analysis is on a specification of the microglia system in a declarative programming language (Maude) but for purposes of providing a cross-check, the same interactions are also represented in an imperative language (MATLABTM). Model elements in the Maude and MATLAB versions have the same names. To distinguish them from biological entities, model element names are rendered in monospace font (see Table S1, ESI[†]). Because model element names correspond to program variable names they substitute lower-case Roman letters for Greek letters.

The model is based on data derived from experiments using molecular biology techniques (*e.g.* gel electrophoresis, immunohistochemistry, phagocytosis assay, *etc.*) that provide relative measures of molecular abundance or activity rather than precise chemical concentrations or reaction rates. For this reason, all model elements are assigned integer levels in the range [0, 10] that represent their relative activity. In Maude all elements are represented as operators that assign an integer level to the element they represent, while in MATLAB all elements are represented simply as variables. For example, in Maude the operator IL1b (7) assigns the level 7 to IL1b while in MATLAB the variable IL1b simply would be set to 7. The slightly more complicated representation in Maude is a requirement of its analytical capabilities.




Fig. 1 Model diagram. Dashed lines connote indirect connections. Arrows and tees connote positive and negative connections, respectively. For abbreviations see Table S1 (ESI†).

Table 1 Truth table. The input elements in the truth table are the inflammatory stimuli Ab and LPS, the compounds rosi and retino, and the initial levels of key cytokines: IFNgini, IL4ini, and IGF1ini. The output elements are those for which consistent experimental results have been reported. The young and old cases are distinguished, respectively, by the presence or absence of the neuronal factors ACh, CD22, CD200, CX3CL1, and TREM2L. All element levels are nonzero integers representing relative activities. Numerals underlined and in bold reflect changes in activity levels that have been observed experimentally and that must be matched by the outputs of both the Maude and MATLAB versions of the microglia signaling model. Numerals in plain font denote output levels for which no matching experimental data yet exist. Italic numerals represent the output levels of two stable states reached by the Maude version that match neither observation nor MATLAB output (see Results)

Row	Inputs							Age	Outputs						
	Ab	LPS	IFNgini	IL4ini	IGF1ini	rosi	retino		IL1b	TNFa	ROS	phago	Ym1	Arg1	IL4
1	0	0	5	5	5	0	0	Young	<u>5</u>	<u>5</u>	<u>5</u>	<u>5</u>	<u>5</u>	<u>5</u>	<u>5</u>
2	1	0	5	5	5	0	0		<u>7</u>	<u>7</u>	<u>7</u>	<u>7</u>	<u>7</u>	<u>7</u>	<u>7</u>
3	0	1	5	5	5	0	0		<u>7</u>	<u>7</u>	<u>7</u>	<u>7</u>	<u>7</u>	<u>7</u>	<u>7</u>
4	0	0	8	5	5	0	0		<u>7</u>	<u>7</u>	<u>5</u>	<u>7</u>	<u>7</u>	<u>7</u>	<u>7</u>
5a	0	0	5	8	5	0	0		<u>5</u>	<u>5</u>	<u>5</u>	<u>7</u>	<u>7</u>	<u>7</u>	<u>5</u>
5b	"	"	"	"	"	"	"		3	<u>3</u>	3	7	7	5	7
6	0	0	5	5	5	0	0	Old	<u>7</u>	<u>7</u>	<u>5</u>	<u>3</u>	<u>7</u>	<u>5</u>	<u>7</u>
7	1	0	5	5	5	0	0		<u>7</u>	<u>7</u>	<u>7</u>	<u>3</u>	<u>7</u>	<u>5</u>	<u>7</u>
8	0	1	5	5	5	0	0		<u>7</u>	<u>7</u>	<u>7</u>	<u>3</u>	<u>7</u>	<u>5</u>	<u>7</u>
9	1	1	5	5	5	0	0		<u>7</u>	<u>7</u>	<u>7</u>	<u>3</u>	<u>3</u>	<u>3</u>	<u>3</u>
10a	1	1	5	8	5	0	0		<u>7</u>	<u>7</u>	<u>7</u>	<u>3</u>	<u>3</u>	<u>3</u>	<u>3</u>
10b	"	"	"	"	"	"	"		3	3	5	<u>7</u>	7	5	7
11	0	0	5	5	8	0	0		3	<u>3</u>	<u>3</u>	<u>7</u>	7	5	7
12	1	0	5	5	5	1	0		<u>3</u>	<u>3</u>	<u>5</u>	<u>7</u>	7	5	<u>7</u>
13	1	0	5	5	5	0	1		3	3	5	<u>7</u>	7	5	7

Declarations in Maude are either equations or rules. Applicable equations must execute but applicable rules may execute or not,

and all equations must execute before any rule can execute (see also Introduction). All of the declarations in the Maude specification, and all of the statements in the MATLAB program, describe how the level of one model element is changed by the levels of certain other model elements. For example, in Maude:

```
MyD88 (X1) IL1R (X2) IRAK (Y) =
MyD88 (X1) IL1R (X2) IRAK (X1 + X2) if Y /= X1 + X2 .
```

While in MATLAB:

```
if IRAK ~= MyD88 + IL1R, IRAK = MyD88 + IL1R;
upFlag = 1; end
```

Both constructions prescribe that the level of IRAK should be equal to the sum of the levels of MyD88 and IL1R. Both are also conditional, so that the level of IRAK will not be reassigned if it is already equal to the sum of the levels of MyD88 and IL1R (note that \neq and \sim mean "not equal" in Maude and MATLAB, respectively). This declaration is an equation in Maude, so it executes whenever it applies. If the level of MyD88 or IRAK changes over the course of simulation or analysis, then this equation will execute and change the level of IRAK. In contrast, in MATLAB a statement executes according to its order in the program. To make the Maude and MATLAB versions operationally more similar, all of the statements in the MATLAB version occur within a while loop that first sets upFlag to 0 and that breaks only if none of the conditionals in the loop execute and set upFlag back to 1. In other words, if any conditional executes then all of the conditionals must be checked again before the MATLAB simulation can terminate. Almost all declarations/statements in both the Maude and MATLAB versions are conditional. The only ones that are not are those that assign the initial levels of the pro- and anti-inflammatory cytokines in the model.

In the Maude version almost all of the declarations are equations. The ones that are rules rather than equations are

those that specify the autocrine interactions, or the levels of the receptors for the pro- and anti-inflammatory factors that are generated by the microglia system itself. A rule in Maude takes the same form as an equation except that the = sign is replaced with =>. The model represents 78 interactions among 107 elements including initial and constitutive levels of some elements that are not shown in Fig. 1. In the Maude version, 9 of these interactions are the rules that set the 9 autocrine receptor responses. Besides being expressed in different languages, all of the interactions are the same in the Maude and MATLAB versions and most of these are very simple. Elements that receive input from one other element simply take the level of their input element. Many other elements receive input from two or three other elements and for these the interaction is either a simple sum or difference (bound at 0) or a max operation. Only 12 of the 78 interactions are more complex, and these determine the activation of an element on the basis of the pattern of its 3 or more inputs.

The most important operational feature of the model is that the interactions that determine autocrine receptor updates occur last, after the levels of the cytokines, factors, and mediators generated by microglia are changed due to other model interactions. This feature is assured in Maude by expressing all autocrine receptor updates as rules, with all other interactions expressed as equations, and in MATLAB by locating all autocrine receptor updates at the end of the while loop that lists all the interactions. Because the microglial autocrine receptors can be activated by factors that microglia themselves produce, the autocrine receptor updates mediate positive-feedback interactions. In the model these feedback loops are governed by two saturation levels, designated as *proSat* and *antiSat*, which determine the maximal level reachable in any model state by the pro- and anti-inflammatory mediators, respectively. The levels of *proSat* and *antiSat* are determined by the levels of the transcription factors in the model, which are determined, in turn, by the signaling cascades that proceed from the receptors for autocrine mediators and also for exogenous factors. The model reaches terminal states (a.k.a. steady states) when the autocrine mediators reach and hold their saturation levels.

It is important to point out that the model is not the product of a machine learning algorithm in which its structure assumes some standard, homogeneous, *a priori* form (e.g. belief network) and an algorithm is used to fit model parameters. On the contrary, model structure is heterogeneous and custom built according to experimental results and in order to bring overall model behavior in line with observation. In this regard the creation of the microglia signaling model is similar to the creation of models of engineered systems in that the Maude specification is set by the modeler on the basis of knowledge of the system being modeled (a.k.a. the target system). The specification is considered valid if its behavior corresponds to that the target system, and analysis of the specification then leads to potential understanding of the target system.

Results and discussion

The results are derived mainly from temporal-logic analysis and state-space search of a declarative specification of the signaling,

transcriptional, and other interactions that determine microglial phenotype in AD. These computationally intensive analysis and search processes, which are characteristic of declarative models, involve generation of the entire state-transition tree by taking all possible trajectories through the state space. Most imperative models, in contrast, take only one, arbitrary trajectory so that computations will be efficient. Because the two modalities are so different it was useful to create both a declarative and an imperative version of the microglia system model and to use the one to check the other. The same interactions were represented in Maude (declarative) and MATLAB (imperative). Maude was used in simulation mode for comparison with MATLAB, in which simulation is the only mode. The two versions produced the same output for all inputs (when Maude produced two terminal states, one of those states always matched the MATLAB output; see next subsection). Prerequisite to model analysis is verification that overall model behavior is consistent with observation.

Overall model behavior

The salient and consistent findings from the literature are summarized in a truth table (Table 1), which shows what is true for the microglia system given these findings. Because available data are qualitative, the findings are expressed in terms of quantized integer levels. The truth table is organized in terms of certain key model elements designated as inputs and outputs. It is also divided into two parts: the top and bottom parts pertain to brain-resident (*in vivo*) or isolated (*in vitro*) microglia from young or old animals, respectively. Isolated microglia pretreated with A β or with inflammatory mediators are considered old for the purposes of the truth table. In the model, the young and old cases differ in that in the young case the factors ACh, CD22, CD200, CX3CL1, and TREM2L are present but in the old case they are absent. These factors are not completely absent in aging brains but assigning them only two levels, 0 in old and 1 in young brains, is sufficient for the purposes of the model. Obviously other factors also differ between young and old animals. These factors can be added to the model as they are identified experimentally.

For the truth table (Table 1), the inputs are the inflammatory stimuli Ab and LPS, the initial cytokine levels IFN γ ini, IL4ini, and IGF1ini, and the signaling modifiers *rosi* and *retino*. The initial cytokine levels are held at 5 or augmented to a level of 8. While some A β is normally present in young and old brains, the input Ab, like the inputs LPS, *rosi*, and *retino*, is limited to levels of 0 and 1 for simplicity in the model. Each input pattern is associated with one (sometimes two) terminal output patterns. The outputs are the pro-inflammatory factors IL1b, TNFa, and ROS, the process phago, and the anti-inflammatory mediators Ym1, Arg1, IL4, IL10, TGFb, and IGF1. For the outputs in the truth table, underlined boldface numerals designate experimental observations that the model had to match. These observations are assigned the integer levels of 3, 5, and 7, corresponding to low, base, and high, respectively. Within the constraints established by known interactions, model creation was focused on bringing its overall

input/output behavior into agreement with these observations. The chosen set of inputs and outputs is obviously not an exhaustive set of the factors to which microglia respond and that they produce, but they are the factors most often examined in experiments on A β effects on microglia.

Both the Maude and MATLAB versions of the model agreed with each other and with the underlined boldface numerals in the truth table. Agreement of both versions with the data on the effects of A β on microglia indicates that the model can be considered as a valid representation of the microglia system. Agreement between the Maude and MATLAB versions provides assurance that agreement with the data is not due to programming error. On the output side of the truth table, plain numerals are model outputs for which no corresponding experimental observations yet exist. All of those can be considered as model predictions.

In constructing the truth table, Maude was run in search mode in order to determine the terminal states of all possible trajectories through the state space. Because the rules in the model expressed autocrine receptor updates, each trajectory represents one of the possible sequences of updates of the autocrine interactions. The truth table (Table 1) shows that, starting from most of the initial states with inputs as specified, the specification reached only one terminal state, meaning that the same state was reached no matter the order of updates of the autocrine interactions. However, that truth table has two paired rows, 5a/5b and 10a/10b, that show two different outputs for the same initial input state. These are the outputs of two stable (a.k.a. terminal) states of the Maude specification for initial states with augmented initial levels of IL4 (*i.e.* IL4ini(8)). The fact that these initial states give rise to two separate terminal states is of significance for the analysis (see below). The MATLAB version, in contrast, reaches only one terminal state from all initial states because it takes only one, arbitrary trajectory through the state space.

For the two paired rows of the truth table, 5a/5b and 10a/10b, the initial level of IL4 is augmented (*i.e.* IL4ini(8)) but the initial levels of IFN γ and IGF1 are at the base level (IFN γ ini(5) and IGF1ini(5)) (Table 1). Also, both *rosi* and *retino* are absent (*rosi*(0) and *retino*(0)). For the row pair 5a/5b, the model is in the young condition and Ab and LPS are both absent (Ab(0) and LPS(0)). For the row pair 10a/10b, the model is in the old condition and both Ab and LPS are present (Ab(1) and LPS(1)). The output numerals in the first member of each pair (5a or 10a) are *italic* to signify that they represent the Maude terminal states that disagree with the relevant observations. The output numerals in the second member of each pair (5b or 10b) agree with the relevant observations. Although they start from very different initial states, the “correct” terminal states (Table 1 rows 5b and 10b) in these cases are very similar. The importance of these states can be appreciated in the context of the other truth table input/output patterns.

For the baseline condition in young microglia, Ab, LPS, *rosi*, and *retino* are all absent and IFN γ ini, IL4ini, and IGF1ini are all at base. The model was arranged so that, in the young case, all the pro- and anti-inflammatory mediators and phagocytosis were at the base level, which is 5 (Table 1 row 1).

All experimentally observed baselines were assigned the level of 5 also, and so all of the base output levels in this condition are underlined and bold in the truth table. If experimental results indicated a significant increase, decrease, or no change in an output for a specific condition and initial input, then that output takes an underlined bold 7, 3, or 5 (corresponding to high, low, or base) in the truth table (Table 1).

Many studies indicate that exposure to A β will cause young microglia to increase A β phagocytosis and production of pro-inflammatory mediators. Paradoxically, A β exposure will also cause young microglia to increase production of anti-inflammatory mediators, the main exceptions being Agr1, which is not affected by A β , and IGF1, which is actually decreased by A β . Largely the same pattern of changes is observed with LPS exposure, and the model agrees with these findings (Table 1 rows 2 and 3). Starting from baseline, experimental studies show that an initial augmentation in IFN γ will increase TNF α but decrease IGF1, while an initial augmentation in IL4 will decrease TNF α but increase IGF1. The model reproduces these findings (Table 1 rows 4 and 5b), and suggests that augmented initial IFN γ produces a microglial state similar to that produced by A β or LPS, while augmented initial IL4 can produce a state in which pro-inflammatory mediators are decreased, phagocytosis is increased, and most anti-inflammatory mediators including IGF1 are increased in young microglia.

These facts may be key to understanding microglial phenotypic conversion with exposure to A β in young animals. They suggest that IFN γ may allow an inflammatory stimulus such as A β to cause increased production of anti-inflammatory mediators also. The fact that IGF1 is often but not always decreased when other anti-inflammatory cytokines including IL4 are increased suggests a special role for IGF1. The fact that the Maude version of the microglia model has two stable states starting from augmented initial IL4, in only one of which is IGF1 increased, suggests that states with increased IGF1 may be difficult for microglia to achieve.

The baseline condition in old microglia is the same as that in young microglia except that old microglia lack ACh and other neuronal membrane-bound or secreted factors that are present in the young condition. Experimental studies show that old microglia have increased production of pro-inflammatory cytokines but decreased phagocytosis. The model agrees with these findings (Table 1 row 6) and suggests that production of certain anti-inflammatory mediators may also be increased in old microglia (see below). Experiments also show that exposure of old microglia to A β or LPS separately causes increased production of pro-inflammatory and many anti-inflammatory mediators (Table 1 rows 7 and 8) and the response is similar to that of young microglia (Table 1 rows 2 and 3) except that phagocytosis is decreased in the old case.

In vitro it is possible to produce a microglial phenotype in which pro-inflammatory cytokines are increased while most (if not all) anti-inflammatory factors are decreased. Specifically, exposure of old microglia to A β and LPS *together* causes increased pro-inflammatory but decreased anti-inflammatory cytokine production. Interestingly, this hyperinflammatory condition as well as the less inflammatory conditions can be

reversed by augmented initial IL4, by augmented IGF1, or by compounds such as rosiglitazone or retinoic acid that enhance IGF1 signaling. The model reproduces this set of findings (Table 1 rows 7–13). Again, the fact that the Maude version has two stable states starting from the old and hyperinflammatory condition and augmented initial IL4, in only one of which are pro-inflammatory mediators decreased but anti-inflammatory mediators increased (Table 1 rows 10a and 10b), suggests that reversal of a potentially hyperinflammatory phenotype in old microglia exposed to A β may be difficult to achieve. The behavior of the model in all of these cases is explored in detail throughout the rest of this section.

Response to A β in the young condition

After the consistency of overall model behavior with observation is established, temporal logic is used to analyse it. In Maude this is done by defining certain properties and then checking whether time-qualified propositions involving those properties are true or false, given specific starting conditions. For example, the property IL1bEQ7 is true when the level of IL1b is 7 (IL1b(7)). Note that 7 corresponds to the high activity level. Then [] IL1bEQ7, where [] is the temporal-logic operator “always”, is the proposition that IL1b is always active at the high level. Thorough understanding of model behavior can be developed by using Maude to determine under what conditions this and other propositions are true.

Table 2 presents a temporal-logic analysis of the model in the young case when Ab is also present (Ab(1)). In this case IL1b is always active at the high level. It is useful to reiterate here that the only rules in the Maude specification are those that update the levels of the receptors for the factors that are produced by microglia. In other words, only the autocrine interactions are expressed as rules; all other interactions are expressed as equations. In Maude, equations only elaborate the state, they do not change the state of the model. In contrast, rules do change the state, and the state transitions produced by rules are the events that advance the state and establish sequential orderings among different states. If IL1b is always active at the high level in the presence of Ab, then it is brought to that level by equations made applicable by Ab(1) right from the start. If IL1b is always high with Ab(1), then Ab(1) brought IL1b to this level through execution of equations and before execution of any rules, even if some or all of the rules are also made applicable by Ab(1).

This analysis will feature IL1b as representative of pro-inflammatory cytokines, and will also feature IFN γ due to its importance in autocrine interactions. Likewise it will feature IL4 as representative of anti-inflammatory cytokines, but will also feature IGF1 because of its unique and important role. Featuring IL1b and IL4 as representative is done to simplify presentation of modeling results, not to imply that IL1 β and IL4 always behave in lockstep with, respectively, other pro- and anti-inflammatory cytokines. For the model in the young case and in the presence of Ab (Ab(1)), IL1b and IFN γ are both always high and NF κ B is likewise always high, signifying a high level of nuclear translocation (Table 2 rows 1 and 2). This

Table 2 Temporal-logic model-checking in the young case with Ab present

Row	Proposition	Value
1	IL1b is always high and IFN γ is always high	True
2	NF κ B is always high	True
3	IL4 is always high or IGF1 is always low	False
4	IL4 is eventually high and IGF1 is eventually low	True
5	PPAR γ is never greater than base	True
6	STAT1 is always high or STAT6 is always high	False
7	STAT1 is eventually high and STAT6 is eventually high	True
8	IL4 is not high or IGF1 is not low until STAT6 is high	False
9	IL4 is not high and IGF1 is not low until STAT1 is high	True
10	STAT1 being high implies that IL4 is high and IGF1 is low	True
11	ROS is always high	True
12	phago is always high	False
13	phago is eventually high	True
14	Smad is always high	False
15	Smad is eventually high	True
16	Smad is not high until STAT1 is high	True
17	STAT1 being high implies phago is high	False
18	STAT1 being high leads to phago being high	True
19	Smad being high implies that phago is high	True

indicates that IL1b and IFN γ are made high directly through signaling *via* the TLR complex and NF κ B without autocrine interaction in the model. The lack of autocrine involvement in this case is *not* a critical feature of the model and could easily be changed if new data suggest that A β requires autocrine amplification in order to produce an inflammatory response. In contrast, signaling pathway structure is a critical model feature, and autocrine interactions figure prominently in the mechanism by which Ab regulates anti-inflammatory cytokines in the model.

In the young case and with Ab(1), IL4 is not always high and IGF1 is not always low, but they both “eventually” reach those levels (Table 2 rows 3 and 4). A signaling molecule of importance in anti-inflammatory regulation is PPAR γ , but the PPAR γ level never rises above base in this case (Table 2 row 5). In contrast, STAT1 and STAT6 are not always but eventually become high (Table 2 rows 6 and 7), indicating that they require autocrine activation in the model. The changes in IL4 and IGF1 due to Ab are due not to STAT6 but to STAT1, since IL4 is not high and IGF1 is not low “until” STAT1 is high. Furthermore, STAT1 being high “implies” that IL4 is high and IGF1 is low (Table 2 rows 8–10). This shows that Ab regulation of IL4 and IGF1 depends on signaling through JAK2 and STAT1, which are activated through autocrine interactions involving IFN γ and IL6 (Fig. 1), and the question arises as to whether both are necessary or only one or the other.

This question is best answered using state-space search. In the young case with Ab(1), IL4 is high, IGF1 is low, and IFN γ and IL6R are both high for the single terminal state Maude reaches in this case (see previous subsection). If the search is expanded to include all states reachable by at least 1 rule execution, which includes the terminal state, and we require that IL4 is high and IGF1 is low, then there are many states (precisely 384, but this number is unimportant) in which either or both of IFN γ and IL6R are high, but there are no states in which IFN γ and IL6R are both low. This proves that Ab regulates

the anti-inflammatory cytokines *via* autocrine interactions requiring IFN γ or IL6 in the model. This interaction is a central feature of model behavior.

In the young case with Ab(1), ROS is always high (Table 2 row 11), indicating that ROS is driven directly through the TLR complex. The same is not also true for phagocytosis. In the young case with Ab(1), phago is not always but is eventually high (Table 2 rows 12 and 13). In the model Smad is the dominant driver of phago, and like phago it is eventually high. Like IL4, Smad is not high until STAT1 is high (Table 2 rows 14–16). STAT1 being high does not imply but does lead to phago being high (Table 2 rows 17 and 18). In contrast, Smad being high does imply that phago is high (Table 2 row 19). This analysis indicates that in the young case, Ab promotes phago largely through an autocrine interaction in which upregulation of pro-inflammatory cytokines such as IFN γ or IL6 leads to JAK2 / STAT1 activation, which leads to generation of anti-inflammatory factors including TGF β , which leads to Smad activation, which increases phago. That Ab promotes phago largely through an autocrine mechanism involving STAT1 signaling is a central model feature (see below in this section).

These interactions account for the differences in model element levels in the young case for Ab(0) *versus* Ab(1) (Table 1 rows 1 and 2). They also account for the differences in element levels in the young case for LPS(0) *versus* LPS(1) (Table 1 rows 1 and 3), because LPS signals through the TLR complex just as Ab does in the model. The temporal-logic analysis just described illustrates how IFN γ (or IL6) provides what could be called an “autocrine bridge” in the model by which an inflammatory response can lead to changes in expression (increases and decreases) of anti-inflammatory factors. An augmentation in the initial level of IFN γ (*i.e.* IFN γ ini(8)) in the young case produces the same changes in cytokine levels and phagocytosis as does Ab(1) or LPS(1) in the model but does not increase ROS, because ROS is driven by TLR activation but that does not occur without Ab or LPS in the model (Table 1 row 4). An augmentation in the initial level of IL4 (*i.e.* IL4ini(8)) in the young case has an entirely different outcome, which is analyzed in the next subsection.

Response to IL4 augmentation in the young condition

An augmentation in the initial level of IL4 (*i.e.* IL4ini(8)) in the young case produces changes in model element levels that differ substantially from those produced by changes in the initial level of IFN γ (Table 1 rows 4, 5a, and 5b). Temporal-logic analysis of the model in the young case with IL4ini(8) is shown in Table 3. In this case, IL1b is not always low and IGF1 is not always high (Table 3 row 1), indicating that the levels of these mediators change due to autocrine interactions in the model. Considered separately, IL1b is not always low and it is not even eventually low (Table 3 rows 2 and 3). The latter is due to the existence of the two stable states associated with this case. From this we know that IL1b is eventually low for paths that lead to one stable state but not the other (Table 1 rows 5a and 5b), so it is not true over all possible paths that IL1b is eventually low.

Table 3 Temporal-logic model-checking in the young case with augmented initial IL4

Row	Proposition	Value
1	IL1b is always low and IGF1 is always high	False
2	IL1b is always low	False
3	IL1b is eventually low	False
4	IGF1 is always high	False
5	IGF1 is eventually high	True
6	STAT6 above high implies that IGF1 is high	True
7	IGF1 being high implies that IGF1 remains high	False
8	IL1b is not low until IGF1 is high	True
9	IGF1 being high leads to IL1b being low	False
10	AP1 being low implies that AP1 remains low	True
11	STAT3 being low implies that STAT3 remains low	True
12	NFkB being low implies that NFkB remains low	True
13	IL1b being low implies that AP1 is low	False
14	IL1b being low implies that STAT3 is low	False
15	IL1b being low implies that NFkB is low	True
16	NFkB is not low until IGF1 is high	True
17	PPARG is not above high until IGF1 is high	True
18	PKC is not above high until IGF1 is high	True
19	Gq is not high until IGF1 is high	True
20	Gq being high implies that IL1b is low	True
21	IGF1 being high leads to Gq being high	False
22	Gq being high implies that IGF1 is high	True
23	Gq being high implies that Gq remains high	True

In contrast, IGF1 is not always high but it is eventually high (Table 3 rows 4 and 5) and this means that IGF1 eventually attains the high level along all paths in the young case with IL4ini(8). IL4 signals through JAK2 and STAT6, and IL4ini(8) pushes STAT6 to a level above high, and STAT6 above high implies that IGF1 is high (Table 3 row 6). Thus, IGF1 is driven high by the initially augmented level of IL4, but it does not always maintain that level because IGF1 being high does not imply that IGF1 remains high (Table 3 row 7). Also, IGF1 needs to be high before IL1b is driven low, but IGF1 being high does not guarantee that IL1b eventually will be low (Table 3 rows 7–9). The analysis so far indicates that, in the young case with IL4ini(8), the stable state in which IL1b is low and IGF1 is high depends on events that occur after the initial activation by IL4ini(8) of anti-inflammatory cytokines.

Temporal logic can be used to see which of the pro-inflammatory transcription factors must be decreased for IL1b to be driven low in the young case with IL4ini(8). These transcription factors are AP1, STAT3, and NFkB. All of these transcription factors are low in the stable state in which IL1b is low, and temporal logic proves that once they get low they stay low (Table 3 rows 10–12). In other words, none of the pro-inflammatory transcription factors fall to the low level and then rise up again. It follows that if IL1b is low before a specific transcription factor is low, then that transcription factor could not be one that causes IL1b to get low. One way to check is to use the strong form of the logical implication operator to see which of the transcription factors are low whenever IL1b is low. The analysis shows that IL1b being low does not imply that AP1 is low or that STAT3 is low, but it does imply that NFkB is low (Table 3 rows 13–15). This proves

that NFkB is the transcription factor responsible for low expression of IL1b in the young case with IL4ini (8).

The foregoing has established that IL1b is not low until IGF1 is high (Table 3 row 8), and that NFkB is the transcription factor that regulates IL1b in the young case with IL4ini (8). It remains to check the pathway from IL1b expression through NFkB and back to IGF1. The elements along this pathway are PPARg, PKC, and Gq (note that available data does not allow complete characterization of this pathway). In the stable state in which IL1b is low, NFkB is also low, PPARg and PKC are above high, and Gq is high. Temporal-logic analysis shows that none of these levels occur until IGF1 is high (Table 3 rows 16–19). Although IGF1 being high does not necessarily lead to IL1b being low (Table 3 row 9), Gq being high implies that IL1b is low (Table 3 row 20). Similarly, IGF1 being high does not necessarily lead to Gq being high, but Gq being high implies that IGF1 is high (Table 3 rows 21 and 22). This seems circular but it is in fact explanatory.

If IGF1 brings Gq to the high level then Gq activates PKC. This leads to enhancement of PPARg, which enhances expression of anti-inflammatory factors including IGF1 itself but suppresses NFkB, which suppresses expression of pro-inflammatory factors. This leads to the “correct” stable state in which IL1b is low and IGF1 is high (Table 1 row 5b). On the other hand, if IGF1 is brought back to base before it can bring Gq to the high level, then PPARg activity is not enhanced. Consequently expression of IGF1 is not enhanced and, for that reason, expression of pro-inflammatory factors is not suppressed. This leads to the stable state in which IL1b and IGF1 are both at the base level (Table 1 row 5a). The abovementioned result that Gq being high implies that IGF1 is high (Table 3 row 22) means that IGF1 is high whenever Gq is high. This in turn means that once IGF1 activates Gq it sustains its own activity because once Gq attains the high level it stays there (Table 3 row 23).

This analysis provides insight into what is perhaps the most critical aspect of the model, which is that, in many cases including those with Ab(1), expression of pro- and anti-inflammatory factors are increased together except for IGF1, expression of which is decreased (Table 1). Importantly, in those cases in which expression of IGF1 is increased, expression of anti-inflammatory factors is also increased but expression of pro-inflammatory factors is decreased (Table 1). These are the cases with the most compelling therapeutic potential and suggest a critical role for IGF1 signaling (see below).

The analysis in the previous subsection shows that IFNg is an autocrine bridge over which a pro-inflammatory trigger such as Ab(1) can also upregulate anti-inflammatory factors. The analysis in this subsection shows that IGF1 is the autocrine bridge over which an overwhelming anti-inflammatory trigger such as IL4ini (8) can downregulate pro-inflammatory factors. Of the two bridges, IGF1 is the more precarious. IFNg can be maintained at the high level through autocrine feedback involving itself and IL1b, IL6, and TNFa, which signal through AP1 and STAT3. In contrast, once brought to the high level by initially augmented IL4ini (8) and STAT6, IGF1 must maintain itself over its pathway from Gq to PKC to PPARg. If it fails to do

so, the therapeutically favorable state in which IGF1 and the other anti-inflammatory factors and phagocytosis are high, but ROS and pro-inflammatory factors are low (Table 1), does not occur. Pharmacological enhancement of PPARg has already been shown to move microglia in the direction of this therapeutically favorable state. The model suggests PKC as another therapeutically advantageous target (see below).

Response to Aβ and LPS in the old condition

What distinguishes the old from the young condition in the model is the absence of ACh and the neuronal surface ligands CD22, CD200, CX3CL1, and TREM2L. The ligand CD40L remains. This reflects a pattern expected in old brains in which neurons, especially cholinergic neurons, are dying, and because CD22, CD200, CX3CL1, and TREM2L are expressed by healthy neurons while CD40L is expressed by necrotic neurons. The effects of these neuronal factors vary but CD22, CD200, CX3CL1, and TREM2L are generally anti-inflammatory while CD40L is pro-inflammatory. In the model the net effect of the loss of CD22, CD200, CX3CL1, and TREM2L is upregulation of pro-inflammatory cytokines, which leads to upregulation of anti-inflammatory cytokines (Table 1 row 6). The latter occurs by crossing the IFNg autocrine bridge as described in the young case in the presence of Ab (see above) but in the old case it also occurs in the absence of Ab. Temporal-logic analysis reveals the basis of the similarities and differences between these two cases.

In the young case with Ab(1), NFkB is always high (Table 2 row 2) because it is set by Ab through the TLR complex (see above). The resulting upregulation of IFNg and IL6 then leads to upregulation of the anti-inflammatory cytokines except for IGF1. In contrast, NFkB is not always high in the old case with Ab(0) but NFkB is eventually high (Table 4 rows 1 and 2), indicating that NFkB is driven up by autocrine feedback in the model. Similarly, STAT3 is not always high but is eventually high (Table 4 rows 3 and 4). The only other transcription factor in the model that could initiate upregulation of the pro-inflammatory cytokines is AP1, and analysis shows that AP1 is always greater than base in the old case without Ab or LPS (Table 4 row 5). Thus, AP1 is the transcription factor responsible for pro-inflammatory upregulation in this case.

In the model, AP1 is driven by p38MAPK and JNK (specifically, AP1 takes whichever of the p38MAPK or JNK levels that is greater), and p38MAPK and JNK are similarly always greater

Table 4 Temporal-logic model-checking in the old case without Ab or LPS

Row	Proposition	Value
1	NFkB is always high	False
2	NFkB is eventually high	True
3	STAT3 is always high	False
4	STAT3 is eventually high	True
5	AP1 is always above base	True
6	p38MAPK is always above base	True
7	JNK is always above base	True
8	IL1b is always high	True
9	IFNg is always high	True

than base (Table 4 rows 6 and 7). The picture that emerges in the old case with Ab(0) is that the absence of CD22, CD200, CX3CL1, and TREM2L pushes p38MAPK and JNK above base, which pushes AP1 above base, and this brings the pro-inflammatory cytokines up to the high level of expression without autocrine feedback since IL1b and IFNg are both always high (Table 4 rows 8 and 9). However, autocrine feedback subsequently pushes p38MAPK, JNK, and AP1 to the high level and slightly above. Again activation of IFNg (or IL6) acts as an autocrine bridge to upregulate the anti-inflammatory cytokines, as it does in the young case with Ab(1), and this accounts for the pattern of expression in the old case with Ab(0).

The output patterns in the young case with Ab(1) and in the old case with Ab(0) are the same with two exceptions (Table 1 rows 2 and 6). The first exception is that ROS is high in the young Ab(1) case but at base in the old Ab(0) case. This difference is easy to explain because ROS is driven by the TLR complex in the model, which is in turn activated by Ab or LPS, neither of which are present in the unstimulated, old case being analyzed here. The second exception is that phago is high in the young Ab(1) case but low in the old Ab(0) case. This situation persists in the old case even when Ab and/or LPS are present (Table 1 rows 6–9), as it must do in order to agree with observation. The interactions that govern phago in the model are set to reproduce these observations based on specific patterns of activity of the elements that determine the level of phago but are not critical model features in themselves.

Experiments show that microglia from aged specimens are inflammatory even without Aβ or LPS as stimuli. The model reflects this (Table 1 row 6) and it follows, due to the IFNg autocrine bridge, that old microglia should produce some anti-inflammatory factors along with the pro-inflammatory cytokines (see below). In the presence either of Ab or LPS in the model, the old output pattern is the same as it is without Ab or LPS, except that ROS is high (Table 1 rows 7 and 8). This result, as described in the previous paragraph, is due to activation of the TLR complex by Ab or LPS.

The output pattern in the old case changes dramatically when Ab and LPS are combined. In the old case with Ab(1) and LPS(1), the pro-inflammatory cytokines IL1b and TNFa remain high, ROS is high, and phago is low, but all the anti-inflammatory factors are driven low. Temporal-logic analysis reveals the basis of this effect. In the old case with Ab(1) and LPS(1), IL1b and IFNg are always high and IL4 is always low (Table 5 rows 1–3), indicating that these pro- and anti-inflammatory cytokine levels do not depend on autocrine feedback in this case. In contrast, IGF1 is not always low but it is eventually low (Table 5 rows 2–4), indicating that the IGF1 level does depend on autocrine interactions in this case. Further analysis reveals the transcription factors responsible for these effects.

NFkB can be driven *via* TAK1 either by pro-inflammatory cytokines or by activation of the TLR complex. In the old case, synergistic activation of the TLR complex by Ab(1) and LPS(1) drives NFkB above high, and this pushes IL1b and IFNg up to

the high level (Table 5 rows 5 and 6). This level of NFkB activation also drives PPARG to the low level, and that pushes IL4 to the low level but does not do the same for IGF1 (Table 5 rows 7–10). With RXR and LXRB at constitutive levels, as they are in this case, the only other transcription factors that could reduce the IGF1 level are STAT1 and STAT6. STAT1 is not always but is eventually high while STAT6 is not always but is eventually low (Table 5 rows 11–14), indicating that the levels of both factors depend on autocrine interactions in the model. Further analysis shows that IGF1 can reach the low level before STAT6 reaches its low level, but IGF1 cannot reach the low level before STAT1 reaches the high level (Table 5 rows 15 and 16). These results prove that STAT1 is the transcription factor responsible for driving down IGF1 in the model in the old case with Ab(1) and LPS(1).

The transcription factor STAT1 is activated by JAK2 following binding of IFNg or IL6 to their receptors. In the model in the old case with Ab(1) and LPS(1), STAT1 is not high until either IFNg or IL6 is high and, given the dependence of IGF1 on STAT1 in this case, it is not surprising that IGF1 is not low until IFNg or IL6 is high (Table 5 rows 17 and 18). These results together show that, in the old case with Ab(1) and LPS(1), IGF1 is driven low over the IFNg autocrine bridge (and IL6 can serve the same bridging function, see next subsection). The reason why the IFNg autocrine bridge does not also activate the other anti-inflammatory cytokines in the old case with Ab(1) and LPS(1), as it does in the young case with either Ab(1) or LPS(1), is that the signal due to STAT1 is overridden by PPARG at the low level (Table 5 row 9). This state, in which all of the pro-inflammatory cytokines are expressed at a high level while all of the anti-inflammatory factors are expressed at a low level, and in which ROS is high but phagocytosis is low, is observed experimentally in old microglia *in vitro* when the TLR complex is synergistically stimulated by Aβ and LPS. This microglial phenotype has not been described as part of AD pathogenesis *in vivo* but obviously it would be devastating if it

Table 5 Temporal-logic model-checking in the old case with Ab and LPS

Row	Proposition	Value
1	IL1b is always high and IFNg is always high	True
2	IL4 is always low and IGF1 is always low	False
3	IL4 is always low	True
4	IGF1 is eventually low	True
5	NFkB is always above high	True
6	NFkB above high implies IL1b is high and IFNg is high	True
7	PPARG is always low	True
8	NFkB above high implies PPARG is low	True
9	PPARG being low implies that IL4 is low	True
10	PPARG being low implies that IGF1 is low	False
11	STAT1 is always high	False
12	STAT1 is eventually high	True
13	STAT6 is always low	False
14	STAT6 is eventually low	True
15	IGF1 is not low until STAT6 is low	False
16	IGF1 is not low until STAT1 is high	True
17	STAT1 is not high until IFNg is high or IL6 is high	True
18	IGF1 is not low until IFNg is high or IL6 is high	True

did occur. Because it can be seen as a hyperinflammatory phenotype it is of interest to see how it could be reversed in the model.

Reversing inflammatory microglial phenotypes

In cultures of microglia from aged animals, a hyperinflammatory phenotype due to the synergistic interaction of A β and LPS can be mitigated with an augmentation in the level of IL4. The same occurs in the model but, as in the young case, the model in the old case with Ab(1) and LPS(1) has two stable states with IL4ini(8) as an initial condition (Table 1 rows 5a, 5b, 10a, and 10b). In one of the states reachable from IL4ini(8) in the old case with Ab(1) and LPS(1), the neurotoxicity is just as extreme as it is without IL4ini(8), but in the other state it is reversed except that ROS is not driven low but returns to base (Table 1 rows 10a and 10b). The mechanisms responsible for this reversal are similar to those described in the young case with IL4ini(8) (Table 3), and the analysis developed in that case (see above) can be abbreviated and re-ordered for this case (Table 6).

As in the young case with IL4ini(8), the augmented initial IL4 level drives STAT6 above high and this pushes IGF1 to the high level (Table 6 row 1). Again as in the young case, if IGF1 then activates Gq before the initially augmented level of IL4 subsides, then IGF1 will sustain itself by driving PKC above high, which will drive PPARG above high, and PPARG will keep IGF1 at the high level (Table 6 rows 2–5). The actual analysis proceeds backward from establishment of the fact that IGF1 is activated by STAT6 above high and once that occurs IGF1 stays high if it activates the pathway from Gq to PKC to PPARG.

As in the young case with IL4ini(8), PPARG above high drives NFkB to the low level and this brings IL1b (Table 6 rows 6 and 7) and the other pro-inflammatory cytokines to the low level also. In contrast, PPARG above high drives IL10 (Table 6 row 8) and the other anti-inflammatory cytokines (including IGF1) to the high level. ROS is initially brought high through activation of the TLR complex by Ab(1) and LPS(1) but it is brought back to base after IGF1 reaches the high level (Table 6 row 9) and suppresses ROS over the PI3K pathway. PPARG above high also drives TGFb high and TGFb then activates phago *via* Smad (Table 6 rows 10–12). In this way the initially augmented level of IL4 reverses what would be a

highly neurotoxic model state into a highly neuroprotective model state. The reversal begins with initial upregulation of IGF1 by IL4 but its consummation hinges on subsequent activation of Gq by IGF1, so the achievement of this neuroprotective state is somewhat precarious. The model offers more direct alternatives.

Experiments show that IGF1 reduces ROS and TNF α production by inflammatory microglia, suggesting that application of IGF1 itself may be a more direct way to achieve the highly neuroprotective state. The model with IGF1ini(8) is consistent with this suggestion (Table 1 row 11). The biological experiments were conducted in the absence of stimulation of the TLR complex and perhaps for that reason IGF1 is able to decrease ROS below its baseline; the same occurs in the model (see Table 1 row 11). Temporal-logic analysis of the model shows that this effect is due to initial and sustained activation of Gq since Gq is always at or above high with IGF1ini(8).

Experiments also show that augmentation of PPAR γ signaling using either rosiglitazone or retinoic acid can decrease expression of pro-inflammatory cytokines, increase expression of anti-inflammatory cytokines, and enhance phagocytosis of A β in old microglia even after stimulation by TLR2/4 ligands. The model reproduces these general findings (Table 1 rows 12 and 13). Temporal-logic analysis of the model in the old case with Ab(1) shows that Gq is eventually high and once high stays high either with rosi(1) or retino(1). These results show that rosi or retino, or IGF1 itself, can activate the Gq pathway and lead to a sustained, neuroprotective state, and they all do so more directly and reliably than IL4. These results suggest that activation of this pathway, which drives the microglia system over the IGF1 autocrine bridge, could be an effective means of pushing inflamed microglia toward a more neuroprotective phenotype.

Main themes and predictions emerging from the model

The main themes that emerge from the model are the potential autocrine bridges involving IFN γ and IGF1. The main predictions from the model focus on these two mechanisms. Experimental data is overwhelmingly consistent with the general finding that activation of the TLR complex by A β leads to increased microglial production of anti-inflammatory as well as pro-inflammatory cytokines. The model suggests that this occurs over an autocrine bridge by which initial upregulation of IFN γ (or IL6), along with other pro-inflammatory cytokines, leads *via* JAK2 and STAT1 to upregulation of IL4, IL10, TGFb, and other anti-inflammatory factors (but downregulation of IGF1; see above). The model predicts that disruption of JAK2 / STAT1 signaling should severely dysregulate this mechanism.

In the model STAT1 is a key player and its removal has complex effects. Removal of STAT1 prevents induction by Ab of the upregulation of Ym1, IL4, IL10, and TGFb that occurs in the model in the young case when STAT1 is present (Table 1 rows 1 and 2; Table 2 rows 3–10). Without STAT1, all of these anti-inflammatory factors stay at baseline, indicating that the autocrine bridge by which Ab upregulates anti-inflammatory factors has been disrupted. Removal of STAT1 also prevents the increase in phago due to Ab that occurs in the model in the

Table 6 Model-checking in the old case with Ab, LPS, and augmented initial IL4

Row	Proposition	Value
1	STAT6 above high implies that IGF1 is high	True
2	Gq being high implies that IGF1 is high	True
3	Gq being high implies that Gq remains high	True
4	PKC is not above high until IGF1 is high	True
5	PPARG is not above high until IGF1 is high	True
6	NFkB is not low until IGF1 is high	True
7	IL1b being low implies that NFkB is low	True
8	IL10 being high implies that PPARG is above high	True
9	ROS is high and not at base until IGF1 is high	True
10	TGFb being high implies that PPARG is above high	True
11	Smad being high implies that TGFb is high	True
12	Smad being high implies that phago is high	True

young case when STAT1 is present (Table 1 rows 1 and 2; Table 2 rows 12–19). In contrast, STAT1 is instrumental in the induction by Ab of downregulation of IGF1 that occurs in the young case when STAT1 is present (Table 1 rows 1 and 2; Table 2 rows 3–10), and removal of STAT1 in the young case in the model actually results in upregulation by Ab of IGF1. Because upregulation of IGF1 results in downregulation of IL1b and other pro-inflammatory cytokines (Table 3 rows 16–20), Ab actually causes downregulation of pro-inflammatory cytokines in the young case when STAT1 is removed. Thus, the model predicts that exposure to A β of young microglia that lack STAT1 should increase production of IGF1 but not of other anti-inflammatory factors, should not increase phagocytosis, and should actually decrease production of pro-inflammatory cytokines, secondary to the increase in IGF1.

Experimental data are also consistent with the general finding that microglia convert to a pro-inflammatory phenotype with age and maintain that phenotype. The model suggests that old microglia could be pushed toward a more neuroprotective phenotype through activation of a pathway from IGF2R through Gq, PKC, and PPAR γ , but that indirect activation of this pathway by upregulation of IGF1 by IL4 may be unreliable (see above). This could explain why old microglia tend to remain in a pro-inflammatory state. Experimental findings show that augmentation of PPAR γ can induce a more neuroprotective phenotype including increased A β phagocytosis, and the model is consistent with these general findings (see above). The model suggests that PKC would also play a critical role in the conversion of the pro-inflammatory phenotype in old microglia to a more neuroprotective state. In the model the effects of removal of PKC are straightforward.

In the model in the old case, the levels of the factors ACh, CD22, CD200, CX3CL1, and TREM2L are switched from 1 to 0, which concisely reflects their reduction with age. In the model in the old case, a hyperinflammatory state, characterized by high and low levels of pro- and anti-inflammatory factors, respectively, and by high ROS but low phago, is brought about by the synergistically inflammatory combination of Ab and LPS (Table 1 row 9). The level of LPS, a pro-inflammatory stimulus derived from the outer membranes of Gram-negative bacteria, could build up with age due to repeated bacterial infections.^{1b} The hyperinflammatory phenotype has not been observed *in vivo*, but something similar to it is plausible in the aged and AD brain due to the possible confluence of low ACh, CD22, CD200, CX3CL1, and TREM2L and high A β and LPS. In the model, this hyperinflammatory phenotype is almost completely reversed by augmented initial IGF1, which brings pro-inflammatory cytokines low, anti-inflammatory factors high, and also brings phago high. The exception to complete reversal is that ROS is not brought low but is returned to base (see above). The straightforward effect of removal of PKC in the model is to completely block the effects of augmented initial IGF1.

In the model, augmented initial IGF1 also reduces pro-inflammatory cytokines in the old case when Ab and LPS are both absent (Table 1 rows 6 and 11), and this is consistent with

observation. Removal of PKC in the model in the old case completely blocks this reduction in pro-inflammatory cytokines. These modeling results point to two model predictions. First, the model posits a hyperinflammatory microglial phenotype in the aged and AD brain that could be reversed by augmented IGF1, but this reversal should depend on PKC. Second, and more generally, the model predicts that any reduction in inflammation due to augmented IGF1 should not occur in the absence of PKC.

These predictions on STAT1 and PKC address the most critical features of the model, but any model result could be considered as a model prediction. For example, on the output side of the truth table (Table 1), any plain numeral can be considered as a prediction of the model concerning an increase, decrease, or no change (respectively 7, 3, or 5) in a factor given the corresponding input conditions on the input side of the truth table. One potentially interesting truth-table prediction concerns microglia from aging brains. Studies of microglia and aging generally do not measure levels of anti-inflammatory cytokines, but the model suggests increased microglial production of IL4, IL10, and other anti-inflammatory cytokines along with the observed increase in production of pro-inflammatory cytokines such as IL1 β and TNF α . The truth-table modeling results also suggest that expression of most anti-inflammatory mediators should be increased whenever expression of IGF1 is increased.

Some questions raised in the modeling process

Aside from adding perspective and making predictions, a model can be useful in identifying pieces missing from the puzzle it strives to fit together. Several missing pieces were identified in the process of specifying the microglia signaling system model. One concerns the mutually antagonistic relationship between PPAR γ and NF κ B that has been uncovered in macrophages.⁶¹ This interaction is a critical feature of the microglia signaling model because it allows IGF1 to suppress production of pro-inflammatory cytokines and to reverse neurotoxic phenotypes. The model predicts that such a mutually antagonistic relationship between PPAR γ and NF κ B should also exist in microglia.

Some of the findings on neuronal membrane-bound or secreted factors are confusing in the context of the model. Some concern fractalkine, which seems consistently to suppress phagocytosis and decrease expression of some pro-inflammatory cytokines but to increase expression of others. How fractalkine signaling can accomplish such cytokine fine tuning is at present unclear. Similarly, activation of TREM2 by TREM2L has been found to reduce the expression of pro-inflammatory cytokines, but TREM2 signals *via* DAP12, which activates Syk. Confusingly, A β activates the TLR complex and that also activates Syk, and this leads to augmentation rather than reduction in expression of pro-inflammatory cytokines. Given the signaling pathways as described so far in the literature and as represented in the model, it is not clear how TREM2 activation could lead to suppression of pro-inflammatory cytokine production.

TREM2 activation has also been shown to promote microglial phagocytosis. In the model, both TREM2 and the TLR complex promote phagocytosis by activating GRB2, which activates ERK (Fig. 1). In order that TREM2 could promote phago but not promote expression of pro-inflammatory cytokines in the model, ERK was not coupled to AP1. Apparently, ERK does activate AP1 in some cells,⁸⁵ but the model suggests ERK does not activate AP1 in microglia. TREM2 has recently emerged as an important player in AD pathogenesis. Further exploration of ERK signaling in microglia could help elucidate the important rule of TREM2 in the AD/inflammatory connection.

Conclusions

Few computational models of the microglial component of AD have appeared. A recent model represents some of the interactions between microglia, astroglia, and neurons that are relevant to A β toxicity, and supports the idea that microglia are central to AD neurodegeneration.⁸⁶ That model is based on differential rate equations and, perforce, makes quantitative assumptions concerning rate parameters. It is different in kind from the microglia signaling model presented here, which is based directly on experimental data and represents signaling interactions in a course-grained fashion that is consistent with the qualitative terms in which the data are described in the literature. The new approach taken here is to use specialized computational techniques to analyze rigorously a system model that a modeler specifies by directly fitting together a large set of individual facts. The model provides a new, high-level view that helps to organize findings and suggest avenues for further research.

The microglia signaling model represents much of what is currently known concerning the effects on microglia of A β , but it is still very far from a complete characterization of microglia. The most immediate direction for continued development of the model is to include more of what is known about microglial signaling. Concerning the inflammatory contribution to AD, an important area for further development is to model inflammatory influences on A β metabolism. The current model treats A β purely as an input, not as an element that is itself dependent on interactions with other model elements. In fact, while A β can activate microglia, the inflammatory response due to microglia can also increase A β production.^{1c} This can occur in at least two ways. First, IL1 β can upregulate amyloid precursor protein (APP),⁸⁷ which is the protein from which A β is derived.³ Second, PPAR γ can downregulate β -secretase (BACE),⁵⁵ one of the two enzymes responsible for the proteolytic processing that produces A β from APP.³ By downregulating PPAR γ , IL1 β and other inflammatory cytokines upregulate BACE. Thus, inflammatory cytokines increase A β by upregulating both BACE and its substrate, APP. Maude-based models of A β metabolism already exist.^{25a,b} By joining these models with the microglia system model, future modeling efforts can close the loop and represent the mutually reinforcing but pathological interaction between A β production and inflammation.

The most critical direction for future development is to couple modeling with experimentation. Because it directly represents experimental findings, model predictions can be tested using the same techniques that were used to generate the data on which the model is based. Using such test results the model can be confirmed or corrected and expanded, new predictions can be generated, and the cycle can be continued, producing a model of ever increasing explanatory power. The main purpose of the modeling described here is to initiate such a computational/experimental interaction.

References

- (a) H. Johnston, H. Boutin and S. M. Allan, Assessing the contribution of inflammation in models of Alzheimer's disease, *Biochem. Soc. Trans.*, 2011, **39**, 886–890, DOI: 10.1042/BST0390886; (b) J. Miklossy, Chronic inflammation and amyloidogenesis in Alzheimer's disease – role of Spirochetes, *J. Alzheimer's Dis.*, 2008, **13**, 381–391; (c) R. von Bernhardi, Glial cell dysregulation: a new perspective on Alzheimer disease, *Neurotoxic. Res.*, 2007, **12**, 215–232; (d) A. Piazza and M. A. Lynch, Neuroinflammatory changes increase the impact of stressors on neuronal function, *Biochem. Soc. Trans.*, 2009, **37**, 303–307, DOI: 10.1042/BST0370303; (e) W. S. Griffin and R. E. Mrak, Interleukin-1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer's disease, *J. Leukocyte Biol.*, 2002, **72**, 233–238; (f) S. Mandrekar-Colucci and G. E. Landreth, Microglia and inflammation in Alzheimer's disease, *CNS Neurol. Disord.: Drug Targets*, 2010, **9**, 156–167.
- C. L. Masters, G. Simms, N. A. Weinman, G. Multhaup, B. L. McDonald and K. Beyreuther, Amyloid plaque core protein in Alzheimer disease and Down syndrome, *Proc. Natl. Acad. Sci. U. S. A.*, 1985, **82**, 4245–4249.
- J. Hardy and D. J. Selkoe, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics, *Science*, 2002, **297**, 353–356, DOI: 10.1126/science.1072994.
- (a) B. Cameron and G. E. Landreth, Inflammation, microglia, and Alzheimer's disease, *Neurobiol. Dis.*, 2010, **37**, 503–509, DOI: 10.1016/j.nbd.2009.10.006; (b) J. J. Bajramovic, Regulation of innate immune responses in the central nervous system, *CNS Neurol. Disord.: Drug Targets*, 2011, **10**, 4–24.
- C. Schwab, A. Klegeris and P. L. McGeer, Inflammation in transgenic mouse models of neurodegenerative disorders, *Biochim. Biophys. Acta*, 2010, **1802**, 889–902, DOI: 10.1016/j.bbdis.2009.10.013.
- (a) P. L. McGeer, M. Schulzer and E. G. McGeer, Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies, *Neurology*, 1996, **47**, 425–432; (b) W. F. Stewart, C. Kawas, M. Corrada and E. J. Metter, Risk of Alzheimer's disease and duration of NSAID use, *Neurology*, 1997, **48**, 626–632; (c) J. C. Anthony, J. C. Breitner, P. P. Zandi, M. R. Meyer, I. Jurasova, M. C. Norton and S. V. Stone,

- Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study, *Neurology*, 2000, **54**, 2066–2071; (d) B. A. in t' Veld, A. Ruitenber, A. Hofman, L. J. Launer, C. M. van Duijn, T. Stijnen, M. M. Breteler and B. H. Stricker, Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease, *N. Engl. J. Med.*, 2001, **345**, 1515–1521, DOI: 10.1056/NEJMoa010178.
- 7 (a) I. R. Mackenzie and D. G. Munoz, Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging, *Neurology*, 1998, **50**, 986–990; (b) I. Alafuzoff, M. Overmyer, S. Helisalmi and H. Soininen, Lower Counts of Astroglia and Activated Microglia in Patients with Alzheimer's Disease with Regular Use of Non-Steroidal Anti-Inflammatory Drugs, *J. Alzheimer's Dis.*, 2000, **2**, 37–46.
 - 8 (a) G. P. Lim, F. Yang, T. Chu, P. Chen, W. Beech, B. Teter, T. Tran, O. Ubeda, K. H. Ashe, S. A. Frautschy and G. M. Cole, Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease, *J. Neurosci.*, 2000, **20**, 5709–5714; (b) Q. Yan, J. Zhang, H. Liu, S. Babu-Khan, R. Vassar, A. L. Biere, M. Citron and G. Landreth, Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease, *J. Neurosci.*, 2003, **23**, 7504–7509; (c) S. Sung, H. Yang, K. Uryu, E. B. Lee, L. Zhao, D. Shineman, J. Q. Trojanowski, V. M. Lee and D. Pratico, Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease, *Am. J. Pathol.*, 2004, **165**, 2197–2206.
 - 9 M. Q. Xia and B. T. Hyman, Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease, *J. NeuroVirol.*, 1999, **5**, 32–41, DOI: 10.3109/13550289909029743.
 - 10 A. R. Simard, D. Soulet, G. Gowing, J. P. Julien and S. Rivest, Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease, *Neuron*, 2006, **49**, 489–502, DOI: 10.1016/j.neuron.2006.01.022.
 - 11 A. Serrano-Pozo, T. Gomez-Isla, J. H. Growdon, M. P. Froesch and B. T. Hyman, A phenotypic change but not proliferation underlies glial responses in Alzheimer disease, *Am. J. Pathol.*, 2013, **182**, 2332–2344, DOI: 10.1016/j.ajpath.2013.02.031.
 - 12 S. Jimenez, D. Baglietto-Vargas, C. Caballero, I. Moreno-Gonzalez, M. Torres, R. Sanchez-Varo, D. Ruano, M. Vizuete, A. Gutierrez and J. Vitorica, Inflammatory response in the hippocampus of PS1M146L/APP751SL mouse model of Alzheimer's disease: age-dependent switch in the microglial phenotype from alternative to classic, *J. Neurosci.*, 2008, **28**, 11650–11661, DOI: 10.1523/JNEUROSCI.3024-08.2008.
 - 13 V. Vasilevko and D. H. Cribbs, Novel approaches for immunotherapeutic intervention in Alzheimer's disease, *Neurochem. Int.*, 2006, **49**, 113–126, DOI: 10.1016/j.neuint.2006.03.019.
 - 14 C. Li, R. Zhao, K. Gao, Z. Wei, M. Y. Yin, L. T. Lau, D. Chui and A. C. Hoi Yu, Astrocytes: implications for neuroinflammatory pathogenesis of Alzheimer's disease, *Curr. Alzheimer Res.*, 2011, **8**, 67–80.
 - 15 J. F. Monin and M. G. Hinchey, *Understanding Formal Methods*, Springer Verlag, London, 2003.
 - 16 M. Huth and M. Ryan, *Logic in Computer Science: Modelling and Reasoning about Systems*, Cambridge University Press, Cambridge, 2nd edn, 2004.
 - 17 (a) S. A. Kauffman, Metabolic stability and epigenesis in randomly constructed genetic nets, *J. Theor. Biol.*, 1969, **22**, 437–467, DOI: 10.1016/0022-5193(69)90015-0; (b) R. Thomas, Boolean formalization of genetic control circuits, *J. Theor. Biol.*, 1973, **42**, 563–585, DOI: 10.1016/0022-5193(73)90247-6; (c) L. Glass and S. A. Kauffman, The logical analysis of continuous, non-linear biochemical control networks, *J. Theor. Biol.*, 1973, **39**, 103–129; (d) L. Glass, Classification of biological networks by their qualitative dynamics, *J. Theor. Biol.*, 1975, **54**, 85–107, DOI: 10.1016/S0022-5193(75)80056-7.
 - 18 (a) S. Klamt, J. Saez-Rodriguez, J. A. Lindquist, L. Simeoni and E. D. Gilles, A methodology for the structural and functional analysis of signaling and regulatory networks, *BMC Bioinf.*, 2006, **7**, 56, DOI: 10.1186/1471-2105-7-56; (b) S. Klamt, J. Saez-Rodriguez and E. D. Gilles, Structural and functional analysis of cellular networks with CellNet-Analyzer, *BMC Syst. Biol.*, 2007, **1**, 2, DOI: 10.1186/1752-0509-1-2; (c) J. Saez-Rodriguez, L. G. Alexopoulos, J. Epperlein, R. Samaga, D. A. Lauffenburger, S. Klamt and P. K. Sorger, Discrete logic modelling as a means to link protein signalling networks with functional analysis of mammalian signal transduction, *Mol. Syst. Biol.*, 2009, **5**, 331, DOI: 10.1038/msb.2009.87.
 - 19 (a) R. Franke, F. J. Theis and S. Klamt, From binary to multivalued to continuous models: the lac operon as a case study, *J. Integr. Bioinf.*, 2010, **7**, DOI: 10.2390/biecoll-jib-2010-151; (b) F. Liu, M. A. Blatke, M. Heiner and M. Yang, Modelling and simulating reaction-diffusion systems using coloured Petri nets, *Comput. Biol. Med.*, 2014, **53**, 297–308; (c) M. Durzinsky, A. Wagler and W. Marwan, Reconstruction of extended Petri nets from time series data and its application to signal transduction and to gene regulatory networks, *BMC Syst. Biol.*, 2011, **5**, 113, DOI: 10.1186/1752-0509-5-113.
 - 20 J. Fisher and T. A. Henzinger, Executable cell biology, *Nat. Biotechnol.*, 2007, **25**, 1239–1249, DOI: 10.1038/nbt1356.
 - 21 (a) M. L. Wynn, N. Consul, S. D. Merajver and S. Schnell, Logic-based models in systems biology: a predictive and parameter-free network analysis method, *Integr. Biol.*, 2012, **4**, 1323–1337, DOI: 10.1039/c2ib20193c; (b) R. Samaga and S. Klamt, Modeling approaches for qualitative and semi-quantitative analysis of cellular signaling networks, *Cell Commun. Signaling*, 2013, **11**, 43, DOI: 10.1186/1478-811X-11-43.
 - 22 M. Clavel, R. Durán, S. Eker, P. Lincoln, N. Martí-Oliet, J. Meseguer and C. Talcott, *All About Maude – A High-Performance Logical Framework: How to Specify, Program, and Verify Systems in Rewriting Logic*, Springer, Berlin, 2007, vol. 4350.
 - 23 J. Meseguer, Twenty years of rewriting logic, *J. Logic Algebr. Progr.*, 2012, **81**, 721–781.
 - 24 (a) S. Eker, M. Knapp, K. Laderoute, P. Lincoln, J. Meseguer and K. Sonmez, Pathway logic: symbolic analysis of biological signalling, *Pac. Symp. Biocomput.*, 2002, 400–412; (b) C. Talcott, in

- Lecture Notes in Computer Science*, ed. M. Bernardo, P. Degano, G. Zavattaro, Springer, Berlin, 2008, vol. 5016, pp. 21–53.
- 25 (a) T. J. Anastasio, Data-driven modeling of Alzheimer disease pathogenesis, *J. Theor. Biol.*, 2011, **290**, 60–72, DOI: 10.1016/j.jtbi.2011.08.038; (b) T. J. Anastasio, Exploring the contribution of estrogen to amyloid-beta regulation: a novel multifactorial computational modeling approach, *Front. Pharmacol.*, 2013, **4**, 16, DOI: 10.3389/fphar.2013.00016; (c) T. J. Anastasio, Computational identification of potential multitarget treatments for ameliorating the adverse effects of amyloid-beta on synaptic plasticity, *Front. Pharmacol.*, 2014, **5**, 85, DOI: 10.3389/fphar.2014.00085.
 - 26 M. Di Carlo, Beta amyloid peptide: from different aggregation forms to the activation of different biochemical pathways, *Eur. Biophys. J.*, 2010, **39**, 877–888, DOI: 10.1007/s00249-009-0439-8.
 - 27 (a) M. E. Bamberger, M. E. Harris, D. R. McDonald, J. Husemann and G. E. Landreth, A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation, *J. Neurosci.*, 2003, **23**, 2665–2674; (b) E. G. Reed-Geaghan, J. C. Savage, A. G. Hise and G. E. Landreth, CD14 and toll-like receptors 2 and 4 are required for fibrillar Abeta-stimulated microglial activation, *J. Neurosci.*, 2009, **29**, 11982–11992, DOI: 10.1523/JNEUROSCI.3158-09.2009; (c) J. Koenigsknecht and G. Landreth, Microglial phagocytosis of fibrillar beta-amyloid through a beta1 integrin-dependent mechanism, *J. Neurosci.*, 2004, **24**, 9838–9846, DOI: 10.1523/JNEUROSCI.2557-04.2004; (d) M. L. D. Udan, D. Ajit, N. R. Crouse and M. R. Nichols, Toll-like receptors 2 and 4 mediate Abeta(1-42) activation of the innate immune response in a human monocytic cell line, *J. Neurochem.*, 2008, **104**, 524–533.
 - 28 (a) D. R. McDonald, K. R. Brunden and G. E. Landreth, Amyloid fibrils activate tyrosine kinase-dependent signaling and superoxide production in microglia, *J. Neurosci.*, 1997, **17**, 2284–2294; (b) C. K. Combs, D. E. Johnson, S. B. Cannady, T. M. Lehman and G. E. Landreth, Identification of microglial signal transduction pathways mediating a neurotoxic response to amyloidogenic fragments of beta-amyloid and prion proteins, *J. Neurosci.*, 1999, **19**, 928–939.
 - 29 B. Wilkinson, J. Koenigsknecht-Talboo, C. Grommes, C. Y. Lee and G. Landreth, Fibrillar beta-amyloid-stimulated intracellular signaling cascades require Vav for induction of respiratory burst and phagocytosis in monocytes and microglia, *J. Biol. Chem.*, 2006, **281**, 20842–20850, DOI: 10.1074/jbc.M600627200.
 - 30 V. D. Bianca, S. Dusi, E. Bianchini, I. Dal Pra and F. Rossi, beta-amyloid activates the O-2 forming NADPH oxidase in microglia, monocytes, and neutrophil, A possible inflammatory mechanism of neuronal damage in Alzheimer's disease, *J. Biol. Chem.*, 1999, **274**, 15493–15499.
 - 31 K. M. Park and W. J. Bowers, Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction, *Cell. Signalling*, 2010, **22**, 977–983, DOI: 10.1016/j.cellsig.2010.01.010.
 - 32 (a) J. J. Jin, H. D. Kim, J. A. Maxwell, L. Li and K. Fukuchi, Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease, *J. Neuroinflammation*, 2008, **5**, 23, DOI: 10.1186/1742-2094-5-23; (b) K. L. Richard, M. Filali, P. Prefontaine and S. Rivest, Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1-42 and delay the cognitive decline in a mouse model of Alzheimer's disease, *J. Neurosci.*, 2008, **28**, 5784–5793, DOI: 10.1523/JNEUROSCI.1146-08.2008; (c) M. Song, J. Jin, J. E. Lim, J. Kou, A. Pattanayak, J. A. Rehman, H. D. Kim, K. Tahara, R. Lalonde and K. Fukuchi, TLR4 mutation reduces microglial activation increases Abeta deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease, *J. Neuroinflammation*, 2011, **8**, 92, DOI: 10.1186/1742-2094-8-92.
 - 33 S. Dennler, M. J. Goumans and P. ten Dijke, Transforming growth factor beta signal transduction, *J. Leukocyte Biol.*, 2002, **71**, 731–740.
 - 34 T. Wyss-Coray, C. Lin, F. Yan, G. Q. Yu, M. Rohde, L. McConlogue, E. Masliah and L. Mucke, TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice, *Nat. Med.*, 2001, **7**, 612–618, DOI: 10.1038/87945.
 - 35 S. S. Shaftel, S. Kyrkanides, J. A. Olschowka, J. N. Miller, R. E. Johnson and M. K. O'Banion, Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology, *J. Clin. Invest.*, 2007, **117**, 1595–1604, DOI: 10.1172/JCI31450.
 - 36 P. Chakrabarty, K. Jansen-West, A. Beccard, C. Ceballos-Diaz, Y. Levites, C. Verbeeck, A. C. Zubair, D. Dickson, T. E. Golde and P. Das, Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition, *FASEB J.*, 2010, **24**, 548–559, DOI: 10.1096/fj.09-141754.
 - 37 (a) J. P. Godbout and R. W. Johnson, Interleukin-6 in the aging brain, *J. Neuroimmunol.*, 2004, **147**, 141–144; (b) S. E. Hickman, E. K. Allison and J. El Khoury, Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice, *J. Neurosci.*, 2008, **28**, 8354–8360, DOI: 10.1523/JNEUROSCI.0616-08.2008.
 - 38 J. Vom Berg, S. Prokop, K. R. Miller, J. Obst, R. E. Kalin, I. Lopategui-Cabezas, A. Wegner, F. Mair, C. G. Schipke, O. Peters, Y. Winter, B. Becher and F. L. Heppner, Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline, *Nat. Med.*, 2012, **18**, 1812–1819.
 - 39 J. M. Craft, D. M. Watterson, E. Hirsch and L. J. Van Eldik, Interleukin 1 receptor antagonist knockout mice show enhanced microglial activation and neuronal damage induced by intracerebroventricular infusion of human beta-amyloid, *J. Neuroinflammation*, 2005, **2**, 15, DOI: 10.1186/1742-2094-2-15.
 - 40 M. Colomiere, A. C. Ward, C. Riley, M. K. Trenerry, D. Cameron-Smith, J. Findlay, L. Ackland and N. Ahmed, Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas, *Br. J. Cancer*, 2009, **100**, 134–144, DOI: 10.1038/sj.bjc.6604794.
 - 41 S. L. Montgomery, M. A. Mastrangelo, D. Habib, W. C. Narrow, S. A. Knowlden, T. W. Wright and W. J. Bowers, Ablation of TNF-RI/RII expression in Alzheimer's disease mice leads to an unexpected enhancement of pathology: implications for chronic pan-TNF-alpha suppressive therapeutic strategies in

- the brain, *Am. J. Pathol.*, 2011, **179**, 2053–2070, DOI: 10.1016/j.ajpath.2011.07.001.
- 42 I. Bulgarelli, L. Tamiasso, E. Bresciani, D. Rapetti, S. Caporali, D. Lattuada, V. Locatelli and A. Torsello, Desacyl-ghrelin and synthetic GH-secretagogue modulate the production of inflammatory cytokines in mouse microglia cells stimulated by beta-amyloid fibrils, *J. Neurosci. Res.*, 2009, **87**, 2718–2727.
 - 43 O. Butovsky, A. E. Talpalar, K. Ben-Yaakov and M. Schwartz, Activation of microglia by aggregated beta-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-gamma and IL-4 render them protective, *Mol. Cell. Neurosci.*, 2005, **29**, 381–393, DOI: 10.1016/j.mcn.2005.03.005.
 - 44 M. Yamamoto, T. Kiyota, M. Horiba, J. L. Buescher, S. M. Walsh, H. E. Gendelman and T. Ikezu, Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice, *Am. J. Pathol.*, 2007, **170**, 680–692, DOI: 10.2353/ajpath.2007.060378.
 - 45 I. R. Turnbull, S. Gilfillan, M. Cella, T. Aoshi, M. Miller, L. Piccio, M. Hernandez and M. Colonna, Cutting edge: TREM-2 attenuates macrophage activation, *J. Immunol.*, 2006, **177**, 3520–3524.
 - 46 (a) J. N. Ihle and I. M. Kerr, Jaks and Stats in signaling by the cytokine receptor superfamily, *Trends Genet.*, 1995, **11**, 69–74; (b) A. Bernardo, G. Levi and L. Minghetti, Role of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and its natural ligand 15-deoxy-Delta12, 14-prostaglandin J2 in the regulation of microglial functions, *Eur. J. Neurosci.*, 2000, **12**, 2215–2223.
 - 47 Y. Y. Grinberg, M. E. Dibbern, V. A. Levasseur and R. P. Kraig, Insulin-like growth factor-1 abrogates microglial oxidative stress and TNF-alpha responses to spreading depression, *J. Neurochem.*, 2013, **126**, 662–672, DOI: 10.1111/jnc.12267.
 - 48 A. M. Fernandez and I. Torres-Aleman, The many faces of insulin-like peptide signalling in the brain, *Nat. Rev. Neurosci.*, 2012, **13**, 225–239, DOI: 10.1038/nrn3209.
 - 49 K. Tahara, H.-D. Kim, J.-J. Jin, J. A. Maxwell, L. Ling and K. Fukuchi, Role of toll-like receptor signalling in A-beta uptake and clearance, *Brain*, 2006, **129**, 3006–3019.
 - 50 A. Sierra, A. C. Gottfried-Blackmore, B. S. McEwen and K. Bulloch, Microglia derived from aging mice exhibit an altered inflammatory profile, *Glia*, 2007, **55**, 412–424, DOI: 10.1002/glia.20468.
 - 51 J. V. Welser-Alves and R. Milner, Microglia are the major source of TNF-alpha and TGF-beta1 in postnatal glial cultures; regulation by cytokines, lipopolysaccharide, and vitronectin, *Neurochem. Int.*, 2013, **63**, 47–53, DOI: 10.1016/j.neuint.2013.04.007.
 - 52 J. P. Michaud, M. Halle, A. Lampron, P. Theriault, P. Prefontaine, M. Filali, P. Tribout-Jover, A. M. Lanteigne, R. Jodoin, C. Cluff, V. Brichard, R. Palmantier, A. Pilorget, D. Larocque and S. Rivest, Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer's disease-related pathology, *Proc. Natl. Acad. Sci. U. S. A.*, 2013, **110**, 1941–1946.
 - 53 J. Koenigsknecht-Talboo and G. E. Landreth, Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines, *J. Neurosci.*, 2005, **25**, 8240–8249, DOI: 10.1523/JNEUROSCI.1808-05.2005.
 - 54 F. S. Shie, R. M. Breyer and T. J. Montine, Microglia lacking E Prostanoid Receptor subtype 2 have enhanced Abeta phagocytosis yet lack Abeta-activated neurotoxicity, *Am. J. Pathol.*, 2005, **166**, 1163–1172.
 - 55 M. Sastre, I. Dewachter, S. Rossner, N. Bogdanovic, E. Rosen, P. Borghgraef, B. O. Evert, L. Dumitrescu-Ozimek, D. R. Thal, G. Landreth, J. Walter, T. Klockgether, F. van Leuven and M. Heneka, Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma, *Proc. Natl. Acad. Sci. U. S. A.*, 2006, **103**, 443–448.
 - 56 M. T. Heneka, M. Sastre, L. Dumitrescu-Ozimek, A. Hanke, I. Dewachter, C. Kuiperi, K. O'Banion, T. Klockgether, F. Van Leuven and G. E. Landreth, Acute treatment with the PPAR-gamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice, *Brain*, 2005, **128**, 1442–1453, DOI: 10.1093/brain/awh452.
 - 57 D. J. Loane, B. F. Deighan, R. M. Clarke, R. J. Griffin, A. M. Lynch and M. A. Lynch, Interleukin-4 mediates the neuroprotective effects of rosiglitazone in the aged brain, *Neurobiol. Aging*, 2009, **30**, 920–931, DOI: 10.1016/j.neurobiolaging.2007.09.001.
 - 58 M. Yamanaka, T. Ishikawa, A. Griep, D. Axt, M. P. Kummer and M. T. Heneka, PPARgamma/RXRalpha-induced and CD36-mediated microglial amyloid-beta phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice, *J. Neurosci.*, 2012, **32**, 17321–17331, DOI: 10.1523/JNEUROSCI.1569-12.2012.
 - 59 N. Zelcer, N. Khanlou, R. Clare, Q. Jiang, E. G. Reed-Geaghan, G. E. Landreth, H. V. Vinters and P. Tontonoz, Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors, *Proc. Natl. Acad. Sci. U. S. A.*, 2007, **104**, 10601–10606, DOI: 10.1073/pnas.0701096104.
 - 60 H. Fan, Y. Guo, X. Liang, Y. Yuan, X. Qi, M. Wang, J. Ma and H. Zhou, Hydrogen sulfide protects against amyloid beta-peptide induced neuronal injury via attenuating inflammatory responses in a rat model, *J. Biomed. Res.*, 2013, **27**, 296–304, DOI: 10.7555/JBR.27.20120100.
 - 61 B. M. Necela, W. Su and E. A. Thompson, Toll-like receptor 4 mediates cross-talk between peroxisome proliferator-activated receptor gamma and nuclear factor-kappaB in macrophages, *Immunology*, 2008, **125**, 344–358, DOI: 10.1111/j.1365-2567.2008.02849.x.
 - 62 (a) J. Tan, T. Town, D. Paris, T. Mori, Z. Suo, F. Crawford, M. P. Mattson, R. A. Flavell and M. Mullan, Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation, *Science*, 1999, **286**, 2352–2355; (b) J. Tan, T. Town, F. Crawford, T. Mori, A. DelleDonne, R. Crescentini, D. Obregon, R. A. Flavell and M. J. Mullan, Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice, *Nat. Neurosci.*, 2002, **5**, 1288–1293, DOI: 10.1038/nn968.

- 63 E. Shimizu, K. Kawahara, M. Kajizono, M. Sawada and H. Nakayama, IL-4-induced selective clearance of oligomeric beta-amyloid peptide(1-42) by rat primary type 2 microglia, *J. Immunol.*, 2008, **181**, 6503–6513.
- 64 (a) R. Guerreiro, A. Wojtas, J. Bras, M. Carrasquillo, E. Rogaeva, E. Majounie, C. Cruchaga, C. Sassi, J. S. Kauwe, S. Younkin, L. Hazrati, J. Collinge, J. Pocock, T. Lashley, J. Williams, J. C. Lambert, P. Amouyel, A. Goate, R. Rademakers, K. Morgan, J. Powell, P. St George-Hyslop, A. Singleton, J. Hardy and Alzheimer Genetic Analysis Group, TREM2 Variants in Alzheimer's Disease, *N. Engl. J. Med.*, 2013, **368**, 117–127; (b) T. Jonsson, H. Stefansson, D. S. Ph, I. Jonsdottir, P. V. Jonsson, J. Snaedal, S. Bjornsson, J. Huttenlocher, A. I. Levey, J. J. Lah, D. Rujescu, H. Hampel, I. Giegling, O. A. Andreassen, K. Engedal, I. Ulstein, S. Djurovic, C. Ibrahim-Verbaas, A. Hofman, M. A. Ikram, C. M. van Duijn, U. Thorsteinsdottir, A. Kong and K. Stefansson, Variant of TREM2 Associated with the Risk of Alzheimer's Disease, *N. Engl. J. Med.*, 2013, **368**, 107–116.
- 65 (a) K. Takahashi, C. D. Rochford and H. Neumann, Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2, *J. Exp. Med.*, 2005, **201**, 647–657, DOI: 10.1084/jem.20041611; (b) H. Neumann and K. Takahashi, Essential role of the microglial triggering receptor expressed on myeloid cells-2 (TREM2) for central nervous tissue immune homeostasis, *J. Neuroimmunol.*, 2007, **184**, 92–99, DOI: 10.1016/j.jneuroim.2006.11.032.
- 66 M. Colonna, TREMs in the immune system and beyond, *Nat. Rev. Immunol.*, 2003, **3**, 445–453, DOI: 10.1038/nri1106.
- 67 (a) C. L. Hsieh, M. Koike, S. C. Spusta, E. C. Niemi, M. Yenari, M. C. Nakamura and W. E. Seaman, A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia, *J. Neurochem.*, 2009, **109**, 1144–1156, DOI: 10.1111/j.1471-4159.2009.06042.x; (b) B. Melchior, A. E. Garcia, B. K. Hsiung, K. M. Lo, J. M. Doose, J. C. Thrash, A. K. Stalder, M. Staufienbiel, H. Neumann and M. J. Carson, Dual induction of TREM2 and tolerance-related transcript, Tmem176b, in amyloid transgenic mice: implications for vaccine-based therapies for Alzheimer's disease, *ASN Neuro*, 2010, **2**, e00037, DOI: 10.1042/AN20100010.
- 68 K. Takahashi, M. Prinz, M. Stagi, O. Chechneva and H. Neumann, TREM2-transduced myeloid precursors mediate nervous tissue debris clearance and facilitate recovery in an animal model of multiple sclerosis, *PLoS Med.*, 2007, **4**, e124, DOI: 10.1371/journal.pmed.0040124.
- 69 J. A. Hamerman, J. R. Jarjoura, M. B. Humphrey, M. C. Nakamura, W. E. Seaman and L. L. Lanier, Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12, *J. Immunol.*, 2006, **177**, 2051–2055.
- 70 R. T. Mott, G. Ait-Ghezala, T. Town, T. Mori, M. Vendrame, J. Zeng, J. Ehrhart, M. Mullan and J. Tan, Neuronal expression of CD22: novel mechanism for inhibiting microglial proinflammatory cytokine production, *Glia*, 2004, **46**, 369–379, DOI: 10.1002/glia.20009.
- 71 A. Lyons, E. J. Downer, S. Crotty, Y. M. Nolan, K. H. Mills and M. A. Lynch, CD200 ligand receptor interaction modulates microglial activation in vivo and in vitro: a role for IL-4, *J. Neurosci.*, 2007, **27**, 8309–8313, DOI: 10.1523/JNEUROSCI.1781-07.2007.
- 72 S. Zhang, H. Cherwinski, J. D. Sedgwick and J. H. Phillips, Molecular mechanisms of CD200 inhibition of mast cell activation, *J. Immunol.*, 2004, **173**, 6786–6793.
- 73 D. G. Walker, J. E. Dalsing-Hernandez, N. A. Campbell and L. F. Lue, Decreased expression of CD200 and CD200 receptor in Alzheimer's disease: a potential mechanism leading to chronic inflammation, *Exp. Neurol.*, 2009, **215**, 5–19, DOI: 10.1016/j.expneurol.2008.09.003.
- 74 (a) J. F. Bazan, K. B. Bacon, G. Hardiman, W. Wang, K. Soo, D. Rossi, D. R. Greaves, A. Zlotnik and T. J. Schall, A new class of membrane-bound chemokine with a CX3C motif, *Nature*, 1997, **385**, 640–644, DOI: 10.1038/385640a0; (b) J. K. Harrison, Y. Jiang, S. Chen, Y. Xia, D. Maciejewski, R. K. McNamara, W. J. Streit, M. N. Salafra, S. Adhikari, D. A. Thompson, P. Botti, K. B. Bacon and L. Feng, Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia, *Proc. Natl. Acad. Sci. U. S. A.*, 1998, **95**, 10896–10901.
- 75 A. E. Cardona, E. P. Piro, M. E. Sasse, V. Kostenko, S. M. Cardona, I. M. Dijkstra, D. Huang, G. Kidd, S. Dombrowski, R. Dutta, J. C. Lee, D. N. Cook, S. Jung, S. A. Lira, D. R. Littman and R. M. Ransohoff, Control of microglial neurotoxicity by the fractalkine receptor, *Nat. Neurosci.*, 2006, **9**, 917–924, DOI: 10.1038/nn1715.
- 76 S. Lee, N. H. Varvel, M. E. Konerth, G. Xu, A. E. Cardona, R. M. Ransohoff and B. T. Lamb, CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models, *Am. J. Pathol.*, 2010, **177**, 2549–2562, DOI: 10.2353/ajpath.2010.100265.
- 77 R. S. Duan, X. Yang, Z. G. Chen, M. O. Lu, C. Morris, B. Winblad and J. Zhu, Decreased fractalkine and increased IP-10 expression in aged brain of APP(swe) transgenic mice, *Neurochem. Res.*, 2008, **33**, 1085–1089, DOI: 10.1007/s11064-007-9554-z.
- 78 T. F. Pais, C. Figueiredo, R. Peixoto, M. H. Braz and S. Chatterjee, Necrotic neurons enhance microglial neurotoxicity through induction of glutaminase by a MyD88-dependent pathway, *J. Neuroinflammation*, 2008, **5**, 43, DOI: 10.1186/1742-2094-5-43.
- 79 P. Davies and A. J. Maloney, Selective loss of central cholinergic neurons in Alzheimer's disease, *Lancet*, 1976, **2**, 1403.
- 80 (a) R. D. Shytle, T. Mori, K. Townsend, M. Vendrame, N. Sun, J. Zeng, J. Ehrhart, A. A. Silver, P. R. Sanberg and J. Tan, Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors, *J. Neurochem.*, 2004, **89**, 337–343, DOI: 10.1046/j.1471-4159.2004.02347.x; (b) R. De Simone, M. A. Ajmone-Cat, D. Carnevale and L. Minghetti, Activation of alpha7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures, *J. Neuroinflammation*, 2005, **2**, 4, DOI: 10.1186/1742-2094-2-4.

- 81 T. Suzuki, I. Hide, A. Matsubara, C. Hama, K. Harada, K. Miyano, M. Andra, H. Matsubayashi, N. Sakai, S. Kohsaka, K. Inoue and Y. Nakata, Microglial $\alpha 7$ nicotinic acetylcholine receptors drive a phospholipase C/IP3 pathway and modulate the cell activation toward a neuroprotective role, *J. Neurosci. Res.*, 2006, **83**, 1461–1470, DOI: 10.1002/jnr.20850.
- 82 W. J. de Jonge and L. Ulloa, The $\alpha 7$ nicotinic acetylcholine receptor as a pharmacological target for inflammation, *Br. J. Pharmacol.*, 2007, **151**, 915–929, DOI: 10.1038/sj.bjp.0707264.
- 83 J. H. Moon, S. Y. Kim, H. G. Lee, S. U. Kim and Y. B. Lee, Activation of nicotinic acetylcholine receptor prevents the production of reactive oxygen species in fibrillar beta amyloid peptide (1-42)-stimulated microglia, *Exp. Mol. Med.*, 2008, **40**, 11–18, DOI: 10.3858/emm.2008.40.1.11.
- 84 H. G. Kim, M. Moon, J. G. Choi, G. Park, A. J. Kim, J. Hur, K. T. Lee and M. S. Oh, Donepezil inhibits the amyloid-beta oligomer-induced microglial activation in vitro and in vivo, *Neurotoxicology*, 2014, **40**, 23–32.
- 85 H. J. Kim, M. H. Lee, H. S. Park, M. H. Park, S. W. Lee, S. Y. Kim, J. Y. Choi, H. I. Shin, H. J. Kim and H. M. Ryoo, Erk pathway and activator protein 1 play crucial roles in FGF2-stimulated premature cranial suture closure, *Dev. Dyn.*, 2003, **227**, 335–346, DOI: 10.1002/dvdy.10319.
- 86 I. K. Puri and L. Li, Mathematical modeling for the pathogenesis of Alzheimer's disease, *PLoS One*, 2010, **5**, e15176, DOI: 10.1371/journal.pone.0015176.
- 87 J. T. Rogers, L. M. Leiter, J. McPhee, C. M. Cahill, S. S. Zhan, H. Potter and L. N. Nilsson, Translation of the alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5'-untranslated region sequences, *J. Biol. Chem.*, 1999, **274**, 6421–6431.